Pfizer (PFE) 10-Q 11 May 22 2022 Q1 Quarterly report Financial data

Cover Page

Cover Page - shares	3 Months Ended
	Apr. 03, 2022	May 06, 2022
Entity Information [Line Items]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Apr. 3, 2022
Document Transition Report	false
Entity File Number	1-3619
Entity Registrant Name	PFIZER INC
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	13-5315170
Entity Address, Address Line One	235 East 42nd Street
Entity Address, City or Town	New York
Entity Address, State or Province	NY
Entity Address, Postal Zip Code	10017
City Area Code	212
Local Phone Number	733-2323
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		5,610,895,801
Entity Central Index Key	0000078003
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q1
Amendment Flag	false
Common Stock, $.05 par value [Member]
Entity Information [Line Items]
Title of 12(b) Security	Common Stock, $.05 par value
Trading Symbol	PFE
Security Exchange Name	NYSE
1.000% Notes due 2027 [Member]
Entity Information [Line Items]
Title of 12(b) Security	1.000% Notes due 2027
Trading Symbol	PFE27
Security Exchange Name	NYSE

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED) - USD ($) shares in Millions, $ in Millions		3 Months Ended
		Apr. 03, 2022	Apr. 04, 2021
Income Statement [Abstract]
Revenues	[1]	$ 25,661	$ 14,516
Costs and expenses:
Cost of sales	[2]	9,984	4,157
Selling, informational and administrative expenses	[2]	2,593	2,777
Research and development expenses	[2]	2,301	1,994
Acquired in-process research and development expenses	[3]	355	19
Amortization of intangible assets		835	858
Restructuring charges and certain acquisition-related costs		192	22
Other (income)/deductions––net		350	(1,004)
Income from continuing operations before provision/(benefit) for taxes on income	[4]	9,050	5,692
Provision/(benefit) for taxes on income		1,172	808
Income from continuing operations		7,879	4,885
Discontinued operations––net of tax		(9)	1
Net income before allocation to noncontrolling interests		7,870	4,886
Less: Net income attributable to noncontrolling interests		6	9
Net income attributable to Pfizer Inc. common shareholders		$ 7,864	$ 4,877
Earnings per common share––basic:
Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share)		$ 1.40	$ 0.87
Discontinued operations––net of tax (in dollars per share)		0	0
Net income attributable to Pfizer Inc. common shareholders (in dollars per share)		1.40	0.87
Earnings per common share––diluted:
Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share)		1.37	0.86
Discontinued operations––net of tax (in dollars per share)		0	0
Net income attributable to Pfizer Inc. common shareholders (in dollars per share)		$ 1.37	$ 0.86
Weighted-average shares––basic		5,617	5,584
Weighted-average shares––diluted		5,758	5,662
[1]	On December 31, 2021, we completed the sale of our Meridian subsidiary. Prior to its sale, Meridian was managed as part of the Hospital therapeutic area. Beginning in the fourth quarter of 2021, the financial results of Meridian were reflected as discontinued operations. Prior-period financial information has been restated, as appropriate. See Note 1A .
[2]	Exclusive of amortization of intangible assets.
[3]	See Note 1D.
[4]	I ncome from continuing operations before provision/(benefit) for taxes on income. Biopharma’s earnings include dividend income from our investment in ViiV of $56 million in the first quarter of 2022 and $27 million in the first quarter of 2021.

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED) - USD ($) $ in Millions		3 Months Ended
		Apr. 03, 2022	Apr. 04, 2021
Statement of Comprehensive Income [Abstract]
Net income before allocation to noncontrolling interests		$ 7,870	$ 4,886
Foreign currency translation adjustments, net		(363)	465
Unrealized holding gains/(losses) on derivative financial instruments, net		203	214
Reclassification adjustments for (gains)/losses included in net income	[1]	(213)	259
Other comprehensive income (loss), derivatives qualifying as hedges, before tax, total		(10)	473
Unrealized holding gains/(losses) on available-for-sale securities, net		(133)	79
Reclassification adjustments for (gains)/losses included in net income	[2]	233	(242)
Other comprehensive income (loss), available-for-sale securities, before tax, total		99	(163)
Reclassification adjustments related to amortization of prior service costs and other, net		(36)	(40)
Reclassification adjustments related to curtailments of prior service costs and other, net		(10)	0
Other		(1)	(3)
Defined benefit plan, amounts recognized in other comprehensive income (loss), net prior service cost, before tax		(47)	(43)
Other comprehensive income/(loss), before tax		(321)	732
Tax provision/(benefit) on other comprehensive income/(loss)		(60)	84
Other comprehensive income/(loss) before allocation to noncontrolling interests		(260)	647
Comprehensive income/(loss) before allocation to noncontrolling interests		7,610	5,533
Less: Comprehensive income/(loss) attributable to noncontrolling interests		6	10
Comprehensive income/(loss) attributable to Pfizer Inc.		$ 7,604	$ 5,523
[1]	Reclassified into Other (income)/deductions—net and Cost of sales. See Note 7E.
[2]	Reclassified into Other (income)/deductions—net.

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Millions		Apr. 03, 2022	Dec. 31, 2021
Assets
Cash and cash equivalents		$ 2,470	$ 1,944
Short-term investments		21,427	29,125
Trade accounts receivable, less allowance for doubtful accounts: 2022—$492; 2021—$492		13,225	11,479
Inventories	[1]	9,979	9,059
Current tax assets		3,117	4,266
Other current assets		4,202	3,820
Total current assets		54,420	59,693
Equity-method investments		15,995	16,472
Long-term investments		4,742	5,054
Property, plant and equipment, less accumulated depreciation: 2022—$15,358; 2021—$15,074		15,109	14,882
Identifiable intangible assets	[2],[3]	29,816	25,146
Goodwill	[4]	50,211	49,208
Noncurrent deferred tax assets and other noncurrent tax assets		5,668	3,341
Other noncurrent assets		7,879	7,679
Total assets		183,841	181,476
Liabilities and Equity
Short-term borrowings, including current portion of long-term debt: 2022—$260; 2021—$1,636		645	2,241
Trade accounts payable		5,506	5,578
Dividends payable		0	2,249
Income taxes payable		3,177	1,266
Accrued compensation and related items		2,249	3,332
Deferred revenues		3,108	3,067
Other current liabilities		24,583	24,939
Total current liabilities		39,268	42,671
Long-term debt		35,656	36,195
Pension benefit obligations		3,261	3,489
Postretirement benefit obligations		233	235
Noncurrent deferred tax liabilities		655	349
Other taxes payable		11,574	11,331
Other noncurrent liabilities		10,508	9,743
Total liabilities		101,155	104,013
Commitments and Contingencies
Common stock		476	473
Additional paid-in capital		90,844	90,591
Treasury stock		(113,931)	(111,361)
Retained earnings		111,193	103,394
Accumulated other comprehensive loss		(6,157)	(5,897)
Total Pfizer Inc. shareholders’ equity		82,424	77,201
Equity attributable to noncontrolling interests		261	262
Total equity		82,685	77,462
Total liabilities and equity		$ 183,841	$ 181,476
[1]	The change from December 31, 2021 reflects increases for Paxlovid and Comirnaty, as well as increases for certain products mainly for network strategy and supply recovery, partially offset by decreases due to market demand.
[2]	The increase in the gross carrying amounts mainly reflect the impact of the acquisition of Arena. See Note 2A .
[3]	The increase is primarily due to the acquisition of Arena, partially offset by amortization expense.
[4]	All goodwill is assigned within the Biopharma reportable segment.

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (PARENTHETICAL) - USD ($) $ in Millions	Apr. 03, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Allowance for doubtful accounts	$ 492	$ 492
Property, plant and equipment, accumulated depreciation	15,358	15,074
Current portion of long-term debt	$ 260	$ 1,636

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF EQUITY (UNAUDITED) - USD ($) shares in Millions, $ in Millions	Total	Shareholders' Equity [Member]	Common Stock [Member]	Add'l Paid-in Capital [Member]	Treasury Stock [Member]	Retained Earnings [Member]	Accum. Other Comp. Loss [Member]		Noncontrolling Interests [Member]
Beginning balance (in shares) at Dec. 31, 2020			9,407		3,840
Beginning balance at Dec. 31, 2020	$ 63,473	$ 63,238	$ 470	$ 88,674	$ (110,988)	$ 90,392	$ (5,310)		$ 235
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	4,886	4,877				4,877			9
Other comprehensive income/(loss), net of tax	647	646					646		1
Cash dividends declared, per share
Common stock	(84)	(84)				(84)
Share-based payment transactions (in shares)			38		11
Share-based payment transactions	(30)	(30)	$ 2	329	$ (361)
Purchases of common stock	0
Other	(27)	(27)				(27)
Ending balance (in shares) at Apr. 04, 2021			9,445		3,851
Ending balance at Apr. 04, 2021	68,865	68,620	$ 472	89,002	$ (111,349)	95,158	(4,664)		245
Beginning balance (in shares) at Dec. 31, 2021			9,471		3,851
Beginning balance at Dec. 31, 2021	77,462	77,201	$ 473	90,591	$ (111,361)	103,394	(5,897)		262
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	7,870	7,864				7,864			6
Other comprehensive income/(loss), net of tax	(260)	(260)					(260)	[1]
Cash dividends declared, per share
Common stock	0
Share-based payment transactions (in shares)			23		12
Share-based payment transactions	(383)	(383)	$ 2	249	$ (570)	(65)
Purchases of common stock (in shares)					(39)
Purchases of common stock	(2,000)	(2,000)			$ (2,000)
Other	(4)	3		3					(7)
Ending balance (in shares) at Apr. 03, 2022			9,494		3,903
Ending balance at Apr. 03, 2022	$ 82,685	$ 82,424	$ 476	$ 90,844	$ (113,931)	$ 111,193	$ (6,157)		$ 261
[1]	Amounts do not include foreign currency translation adjustments attributable to noncontrolling interests. Foreign currency translation adjustments include net losses related to our equity method investment in the Consumer Healthcare JV (see Note 2C ) and the impact of our net investment hedging program.

CONDENSED CONSOLIDATED STATEM_4

CONDENSED CONSOLIDATED STATEMENTS OF EQUITY (UNAUDITED) (PARENTHETICAL) - $ / shares	3 Months Ended
	Apr. 03, 2022	Apr. 04, 2021
Statement of Stockholders' Equity [Abstract]
Cash dividends declared per share (in dollars per share)	$ 0	$ 0

CONDENSED CONSOLIDATED STATEM_5

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($) $ in Millions	3 Months Ended
	Apr. 03, 2022	Apr. 04, 2021
Operating Activities
Net income before allocation to noncontrolling interests	$ 7,870	$ 4,886
Discontinued operations––net of tax	(9)	1
Net income from continuing operations before allocation to noncontrolling interests	7,879	4,885
Adjustments to reconcile net income before allocation to noncontrolling interests to net cash provided by operating activities:
Depreciation and amortization	1,187	1,207
Asset write-offs and impairments	31	24
Deferred taxes from continuing operations	(2,321)	203
Share-based compensation expense	86	172
Benefit plan contributions in excess of expense/income	(404)	(373)
Other adjustments, net	815	(291)
Other changes in assets and liabilities, net of acquisitions and divestitures	(730)	(1,281)
Net cash provided by operating activities from continuing operations	6,541	4,546
Net cash provided by/(used in) operating activities from discontinued operations	0	(8)
Net cash provided by operating activities	6,541	4,538
Investing Activities
Purchases of property, plant and equipment	(643)	(554)
Purchases of short-term investments	(8,758)	(6,054)
Proceeds from redemptions/sales of short-term investments	13,421	5,465
Net (purchases of)/proceeds from redemptions/sales of short-term investments with original maturities of three months or less	3,409	(996)
Purchases of long-term investments	(676)	(27)
Proceeds from redemptions/sales of long-term investments	52	256
Acquisition of business, net of cash acquired	(6,225)	0
Other investing activities, net	(13)	163
Net cash provided by/(used in) investing activities from continuing operations	567	(1,746)
Net cash provided by/(used in) investing activities from discontinued operations	0	0
Net cash provided by/(used in) investing activities	567	(1,747)
Financing Activities
Net (payments on)/proceeds from short-term borrowings with original maturities of three months or less	(220)	(25)
Principal payments on long-term debt	(1,609)	0
Purchases of common stock	(2,000)	0
Cash dividends paid	(2,249)	(2,172)
Other financing activities, net	(501)	(610)
Net cash provided by/(used in) financing activities	(6,578)	(2,807)
Effect of exchange-rate changes on cash and cash equivalents and restricted cash and cash equivalents	(1)	0
Net increase/(decrease) in cash and cash equivalents and restricted cash and cash equivalents	529	(15)
Cash and cash equivalents and restricted cash and cash equivalents, at beginning of period	1,983	1,825
Cash and cash equivalents and restricted cash and cash equivalents, at end of period	2,513	1,809
Cash paid during the period for:
Income taxes	354	394
Interest paid	453	445
Interest rate hedges	$ 26	$ 10

Basis of Presentation and Signi

Basis of Presentation and Significant Accounting Policies	3 Months Ended
	Apr. 03, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation and Significant Accounting Policies	Basis of Presentation and Significant Accounting Policies A. Basis of Presentation We prepared these condensed consolidated financial statements in conformity with U.S. GAAP, consistent in all material respects with those applied in our 2021 Form 10-K. As permitted under the SEC requirements for interim reporting, certain footnotes or other financial information have been condensed or omitted. These financial statements include all normal and recurring adjustments that are considered necessary for the fair statement of results for the interim periods presented. The information included in this Form 10-Q should be read in conjunction with the consolidated financial statements and accompanying notes included in our 2021 Form 10-K . Revenues, expenses, assets and liabilities can vary during each quarter of the year. Therefore, the results and trends in these interim financial statements may not be representative of those for the full year. Pfizer’s fiscal quarter-end for subsidiaries operating outside the U.S. is as of and for the three months ended February 27, 2022 and February 28, 2021, and for U.S. subsidiaries is as of and for the three months ended April 3, 2022 and April 4, 2021. At the beginning of our fiscal fourth quarter of 2021, we reorganized our commercial operations and began to manage our commercial operations through a new global structure consisting of two operating segments, each led by a single manager: Biopharma, our innovative science-based biopharmaceutical business, and PC1, our global contract development and manufacturing organization and a leading supplier of specialty active pharmaceutical ingredients. Biopharma is the only reportable segment. See Note 17A in our 2021 Form 10-K and Note 13 below . Business development activities completed in 2022 and 2021 impacted financial results in the periods presented. Discontinued operations in the periods presented relate to the previously divested Meridian subsidiary, Mylan-Japan collaboration and Upjohn Business. See Notes 1A and 2B in our 2021 Form 10-K, and Note 2B below. We have made certain reclassification adjustments to conform prior-period amounts to the current presentation for discontinued operations and segment reporting. B. New Accounting Standard Adopted in 2022 On January 1, 2022, we early adopted a new accounting standard for contract assets and contract liabilities acquired in a business combination. Under the new standard, acquired contract assets and contract liabilities are required to be recognized and measured by the acquirer on the acquisition date in accordance with ASC 606. This new guidance generally results in the acquirer recognizing contract assets and contract liabilities at the same amounts that were recorded by the acquiree. Previously, these amounts were recognized by the acquirer at fair value as of the acquisition date. We adopted this new standard on a prospective basis and there was no impact to our consolidated financial statements. C. Revenues and Trade Accounts Receivable Revenue Recognition–– We record revenues from product sales when there is a transfer of control of the product from us to the customer. We typically determine transfer of control based on when the product is shipped or delivered and title passes to the customer. For certain contracts, the finished product may temporarily be stored at our location under a bill-and-hold arrangement. Revenue is recognized on bill-and-hold arrangements at the point in time when the customer obtains control of the product and all of the following criteria have been met: the arrangement is substantive; the product is identified separately as belonging to the customer; the product is ready for physical transfer to the customer; and we do not have the ability to use the product or direct it to another customer. In determining when the customer obtains control of the product, we consider certain indicators, including whether we have a present right to payment from the customer, whether title and/or significant risks and rewards of ownership have transferred to the customer and whether customer acceptance has been received. Customers–– Our prescription pharmaceutical products, with the exception of Paxlovid, are sold principally to wholesalers, but we also sell directly to retailers, hospitals, clinics, government agencies and pharmacies. We principally sell Paxlovid to government agencies. In the U.S., we primarily sell our vaccine products directly to the federal government, CDC, wholesalers, individual provider offices, retail pharmacies and integrated delivery networks. Outside the U.S., we primarily sell our vaccines to government and non-government institutions. Deductions from Revenues–– Our accruals for Medicare, Medicaid and related state program and performance-based contract rebates, chargebacks, sales allowances and sales returns and cash discounts are as follows: (MILLIONS) April 3, December 31, 2021 Reserve against Trade accounts receivable, less allowance for doubtful accounts $ 933 $ 1,077 Other current liabilities : Accrued rebates 3,858 3,811 Other accruals 440 528 Other noncurrent liabilities 299 433 Total accrued rebates and other sales-related accruals $ 5,530 $ 5,850 Trade Accounts Receivable–– Trade accounts receivable are stated at their net realizable value. The allowance for credit losses reflects our best estimate of expected credit losses of the receivables portfolio determined on the basis of historical experience, current information, and forecasts of future economic conditions. In developing the estimate for expected credit losses, trade accounts receivables are segmented into pools of assets depending on market (U.S. versus international), delinquency status, and customer type (high risk versus low risk and government versus non-government), and fixed reserve percentages are established for each pool of trade accounts receivables. In determining the reserve percentages for each pool of trade accounts receivables, we considered our historical experience with certain customers and customer types, regulatory and legal environments, country and political risk, and other relevant current and future forecasted macroeconomic factors. These credit risk indicators are monitored on a quarterly basis to determine whether there have been any changes in the economic environment that would indicate the established reserve percentages should be adjusted, and are considered on a regional basis to reflect more geographic-specific metrics. Additionally, write-offs and recoveries of customer receivables are tracked against collections on a quarterly basis to determine whether the reserve percentages remain appropriate. When management becomes aware of certain customer-specific factors that impact credit risk, specific allowances for these known troubled accounts are recorded. Trade accounts receivable are written off after all reasonable means to collect the full amount (including litigation, where appropriate) have been exhausted. During the three months ended April 3, 2022 and April 4, 2021, additions to the allowance for credit losses, write-offs and recoveries of customer receivables were not material to our condensed consolidated financial statements. For additional information on our trade accounts receivable, see Note 1H in our 2021 Form 10-K. D. Acquired In-Process Research and Development Expenses In the first quarter of 2022, we began reporting acquired IPR&D expense as a separate line item in our consolidated statements of income. Acquired in-process research and development expenses includes costs incurred in connection with (a) all upfront and milestone payments on collaboration and in-license agreements, including premiums on equity securities and (b) asset acquisitions of acquired IPR&D. These costs were previously recorded in Research and development expenses . Prior periods have been revised to conform to the current period presentation. When we acquire net assets that do not constitute a business, as defined in U.S. GAAP, no goodwill is recognized and acquired IPR&D is expensed. The fair value of IPR&D acquired in connection with a business combination is recorded on the balance sheet as Identifiable intangible assets . See Notes 1E and 10 in our 2021 Form 10-K .

Acquisition, Discontinued Opera

Acquisition, Discontinued Operations, Equity-Method Investment and Collaborative Arrangement	3 Months Ended
	Apr. 03, 2022
Business Combinations, Disposal Groups, Including Discontinued Operations, Equity Method Investments And Research And Development Arrangement [Abstract]
Acquisition, Discontinued Operations, Equity-Method Investment and Collaborative Arrangement	Acquisition, Discontinued Operations, Equity-Method Investment and Collaborative Arrangement A. Acquisition Arena–– On March 11, 2022, we acquired Arena, a clinical stage company, for $100 per share in cash. The total fair value of the consideration transferred was $6.6 billion ($6.2 billion, net of cash acquired). In addition, $138 million in payments to Arena employees for the fair value of previously unvested long-term incentive awards was recognized as post-closing compensation expense and recorded in Restructuring charges and certain acquisition-related costs (see Note 3 ). Arena’s portfolio includes development-stage therapeutic candidates in gastroenterology, dermatology, and cardiology, including etrasimod, an oral, selective sphingosine 1-phosphate (S1P) receptor modulator currently in development for a range of immuno-inflammatory diseases including UC, Crohn’s Disease, atopic dermatitis, eosinophilic esophagitis, and alopecia areata. In connection with this acquisition, we provisionally recorded: (i) $5.5 billion in Identifiable intangible assets , consisting of $5.0 billion of IPR&D and $460 million of indefinite-lived Licensing agreements, (ii) $1.0 billion of Goodwill and (iii) $510 million of net deferred tax liabilities. The allocation of the consideration transferred to the assets acquired and the liabilities assumed has not yet been finalized. B. Discontinued Operations Meridian–– On December 31, 2021, we completed the sale of our Meridian subsidiary. In the three months ended April 3, 2022, the amounts recorded under the interim TSAs and MSA were not material. Upjohn Separation and Combination with Mylan–– On November 16, 2020, we completed the spin-off and the combination of the Upjohn Business with Mylan to form Viatris. In connection with this transaction, Pfizer and Viatris entered into various agreements to effect the separation and combination and to provide a framework for our relationship after the combination, including a separation and distribution agreement, interim operating models, including agency arrangements, MSAs, TSAs, a tax matters agreement, and an employee matters agreement, among others. The amounts recorded under these agreements were not material to our consolidated results of operations in the three months ended April 3, 2022 and April 4, 2021. Net amounts due from Viatris under the agreements were approximately $133 million as of April 3, 2022 and $53 million as of December 31, 2021. The cash flows associated with the agreements are included in Net cash provided by operating activities from continuing operations, except for a $277 million payment to Viatris made in the first quarter of 2021 pursuant to terms of the separation agreement, which is reported in Other financing activities, net . C. Equity-Method Investment Consumer Healthcare JV–– On July 31, 2019, we completed a transaction in which we and GSK combined our respective consumer healthcare businesses into a new JV that operates globally under the GSK Consumer Healthcare name. In exchange, we received a 32% equity stake in the new company and GSK owns the remaining 68%. We are accounting for our interest in the Consumer Healthcare JV as an equity-method investment. The carrying value of our investment in the Consumer Healthcare JV is $15.8 billion as of April 3, 2022 and $16.3 billion as of December 31, 2021 and is reported as a private equity investment in Equity-method investments as of April 3, 2022 and December 31, 2021. The Consumer Healthcare JV is a foreign investee whose reporting currency is the U.K. pound, and therefore we translate its financial statements into U.S. dollars and recognize the impact of foreign currency translation adjustments in the carrying value of our investment and in other comprehensive income. The decrease in the value of our investment from December 31, 2021 is primarily due to $508 million in pre-tax foreign currency translation adjustments (see Note 6 ), as well as dividends totaling approximately $177 million, partially offset by our share of the JV’s earnings. We record our share of earnings from the Consumer Healthcare JV on a quarterly basis on a one-quarter lag in Other (income)/deductions––net . Our total share of the JV’s earnings generated in the fourth quarter of 2021, which we recorded in our operating results in the first quarter of 2022, was $185 million. Our total share of the JV’s earnings generated in the fourth quarter of 2020, which we recorded in our operating results in first quarter 2021, was $71 million. The total amortization and adjustment of basis differences resulting from the excess of the initial fair value of our investment over the underlying equity in the carrying value of the net assets of the JV is included in Other (income)/deductions––net and was not material to our results of operations in the periods presented. See Note 4. Summarized financial information for our equity method investee, the Consumer Healthcare JV, for the three months ending December 31, 2021, the most recent period available, and for the three months ending December 31, 2020, is as follows: Three Months Ended (MILLIONS) December 31, 2021 December 31, 2020 Net sales $ 3,420 $ 3,096 Cost of sales (1,312) (1,188) Gross profit $ 2,108 $ 1,908 Income from continuing operations 590 233 Net income 590 233 Income attributable to shareholders 578 221 In connection with GSK’s previously announced planned demerger of at least 80% of GSK’s 68% equity interest in the Consumer Healthcare JV, in March 2022 the Consumer Healthcare JV completed its offering of a total aggregate principal amount of $8.75 billion in U.S. dollar-denominated senior notes of various maturities, €2.35 billion in euro-denominated senior notes of various maturities and £700 million in U.K. pound-denominated senior notes of various maturities (collectively, the “notes”). The notes are guaranteed by GSK generally up to and excluding the date of the demerger (the “Guarantee Assumption Date”). We have agreed to indemnify GSK for 32% (representing our pro rata equity interest in the Consumer Healthcare JV) of any amount payable by GSK pursuant to its guarantee of the notes. Our indemnity is provided solely for the benefit of GSK and will terminate automatically as of the Guarantee Assumption date. Neither we nor any of our subsidiaries is an issuer or guarantor of any of the notes. Following its issuance of the notes in March 2022, in our fiscal second quarter of 2022, the Consumer Healthcare JV loaned to us and GSK the net proceeds received from the notes on a pro rata equity ownership basis, for which we received a loan of £2.9 billion, at an interest rate of 1.365% per annum payable semi-annually in arrears. The loan will mature and be repaid upon the earlier of two business days after approval of the demerger transaction by GSK’s shareholders or two business days after the occurrence of a mandatory redemption event with respect to the notes. In conjunction with the demerger, we will receive our 32% share of the proceeds repaid by us and GSK as a dividend from the Consumer Healthcare JV. D. Collaboration Arrangement Collaboration with Biohaven–– In November 2021, we entered into a collaboration and license agreement and related sublicense agreement with Biohaven to commercialize rimegepant and zavegepant for the treatment and prevention of migraines outside of the U.S., subject to regulatory approval. Biohaven will continue to lead R&D globally and we have the exclusive right to commercialization globally, outside of the U.S. Upon the closing of the transaction on January 4, 2022, we paid Biohaven $500 million, including an upfront payment of $150 million and an equity investment of $350 million. We recognized $263 million for the upfront payment and premium paid on our equity investment in Acquired in-process research and development expenses . Biohaven is also eligible to receive up to $740 million in non-U.S. commercialization milestone payments, in addition to tiered double-digit royalties on net sales outside of the U.S. In addition to the milestone payments and royalties above, we will also reimburse Biohaven for the portion of certain additional milestone payments and royalties due to third parties in accordance with preexisting Biohaven agreements, which are attributed to ex-U.S. sales.

Restructuring Charges and Other

Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives	3 Months Ended
	Apr. 03, 2022
Restructuring and Related Activities [Abstract]
Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives	Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives A. Transforming to a More Focused Company Program With the formation of the Consumer Healthcare JV in 2019 and the spin-off of our Upjohn Business in the fourth quarter of 2020, Pfizer has transformed into a focused, global leader in science-based innovative medicines and vaccines. We have undertaken efforts to ensure our cost base and support model align appropriately with our new operating structure. While certain direct costs transferred to the Consumer Healthcare JV, and to the Upjohn Business in connection with the spin-off, there are indirect costs which did not transfer. This program is primarily composed of the following three initiatives: • We are taking steps to restructure our corporate enabling functions to appropriately support our business, R&D and PGS platform functions. We expect costs, primarily related to restructuring our corporate enabling functions, to total $1.8 billion, with substantially all costs to be cash expenditures. Actions include, among others, changes in location of certain activities, expanded use and co-location of centers of excellence and shared services, and increased use of digital technologies. The associated actions and the specific costs will primarily include severance and benefit plan impacts, exit costs as well as associated implementation costs. • In addition, we are transforming our commercial go-to market model in the way we engage patients and physicians. We expect costs of $1.1 billion, with substantially all costs to be cash expenditures. Actions include, among others, centralization of certain activities and enhanced use of digital technologies. The costs for this effort primarily include severance and associated implementation costs. • We are also optimizing our manufacturing network under this program and incurring one-time costs for cost-reduction initiatives related to our manufacturing operations. We expect to incur costs of $800 million, with approximately 25% of the costs to be non-cash. The costs for this effort include, among other things, severance costs, implementation costs, product transfer costs, site exit costs, as well as accelerated depreciation. The program costs discussed above are expected to be incurred primarily from 2020 through 2022, and may be rounded and represent approximations. From the start of this program in the fourth quarter of 2019 through April 3, 2022, we incurred costs of $2.3 billion, of which $875 million is associated with Biopharma ($20 million in 2022, $712 million in 2021, $79 million in 2020 and $64 million in 2019). B. Key Activities The following summarizes acquisitions and cost-reduction/productivity initiatives costs and credits: Three Months Ended (MILLIONS) April 3, April 4, Restructuring charges/(credits): Employee terminations $ 25 $ 22 Asset impairments 8 (5) Exit costs/(credits) 11 — Restructuring charges/(credits) (a) 43 17 Transaction costs (b) 6 — Integration costs and other (c) 142 5 Restructuring charges and certain acquisition-related costs 192 22 Net periodic benefit costs/(credits) recorded in Other (income)/deductions––net (6) 8 Additional depreciation––asset restructuring recorded in our condensed consolidated statements of income, mainly in Cost of sales (d) 9 6 Implementation costs recorded in our condensed consolidated statements of income as follows (e) : Cost of sales 12 11 Selling, informational and administrative expenses 74 64 Total implementation costs 85 75 Total costs associated with acquisitions and cost-reduction/productivity initiatives $ 280 $ 111 (a) Primarily represents cost reduction initiatives. (b) Represents external costs for banking, legal, accounting and other similar services. (c) Represents external, incremental costs directly related to integrating acquired businesses, such as expenditures for consulting and the integration of systems and processes, and certain other qualifying costs. In the first quarter of 2022, integration costs and other were mostly related to our acquisition of Arena, including $138 million in payments to Arena employees for the fair value of previously unvested long-term incentive awards. See Note 2A. (d) Represents the impact of changes in the estimated useful lives of assets involved in restructuring actions. (e) Represents external, incremental costs directly related to implementing our non-acquisition-related cost-reduction/productivity initiatives. The following summarizes the components and changes in restructuring accruals: (MILLIONS) Employee Asset Exit Costs Accrual Balance, December 31, 2021 (a) $ 1,014 $ — $ 57 $ 1,071 Provision 25 8 11 43 Utilization and other (b) (95) (8) (59) (163) Balance, April 3, 2022 (c) $ 943 $ — $ 9 $ 952 (a) Included in Other current liabilities ($816 million) and Other noncurrent liabilities ($255 million). (b) Includes adjustments for foreign currency translation. (c) Included in Other current liabilities ($812 million) and Other noncurrent liabilities ($140 million).

Other (Income)_Deductions - Net

Other (Income)/Deductions - Net	3 Months Ended
	Apr. 03, 2022
Other Income and Expenses [Abstract]
Other (Income)/Deductions - Net	Other (Income)/Deductions—Net Components of Other (income)/deductions––net include: Three Months Ended (MILLIONS) April 3, April 4, Interest income $ (14) $ — Interest expense 322 336 Net interest expense 308 336 Royalty-related income (173) (176) Net (gains)/losses on asset disposals (1) (39) Net (gains)/losses recognized during the period on equity securities (a) 699 (401) Income from collaborations, out-licensing arrangements and sales of compound/product rights (b) (9) (231) Net periodic benefit costs/(credits) other than service costs (283) (266) Certain legal matters, net 79 51 Consumer Healthcare JV equity method (income)/loss (c) (184) (62) Other, net (88) (216) Other (income)/deductions––net $ 350 $ (1,004) (a) The losses in the first quarter of 2022 include, among other things, unrealized losses of $473 million related to our investment in BioNTech. The gains in the first quarter of 2021 included, among other things, unrealized gains of $409 million related to investments in Allogene Therapeutics, Inc. and BioNTech. (b) The first quarter of 2021 included, among other things, $188 million of net collaboration income from BioNTech related to Comirnaty. (c) See Note 2C .

Tax Matters

Tax Matters	3 Months Ended
	Apr. 03, 2022
Income Tax Disclosure [Abstract]
Tax Matters	Tax Matters A. Taxes on Income from Continuing Operations Our effective tax rate for continuing operations was 12.9% for the first quarter of 2022, compared to 14.2% for the first quarter of 2021. The lower effective tax rate for the first quarter of 2022 was primarily due to the favorable change in the jurisdictional mix of earnings as a result of operating fluctuations in the normal course of business. We elected, with the filing of our 2018 U.S. Federal Consolidated Income Tax Return, to pay our initial estimated $15 billion repatriation tax liability on accumulated post-1986 foreign earnings over eight years through 2026. The fourth annual installment of this liability was paid by its April 18, 2022 due date and is reported in current Income taxes payable and the remaining liability is reported in noncurrent Other taxes payable as of April 3, 2022 . Our obligations may vary as a result of changes in our uncertain tax positions and/or availability of attributes such as foreign tax and other credit carryforwards. B. Tax Contingencies We are subject to income tax in many jurisdictions, and a certain degree of estimation is required in recording the assets and liabilities related to income taxes. All of our tax positions are subject to audit by the local taxing authorities in each tax jurisdiction. These tax audits can involve complex issues, interpretations and judgments and the resolution of matters may span multiple years, particularly if subject to negotiation or litigation. The U.S. is one of our major tax jurisdictions, and we are regularly audited by the IRS. With respect to Pfizer, the IRS has issued Revenue Agent’s Reports (RARs) for tax years 2011-2013 and 2014-2015. We are not in agreement with the RARs and are currently appealing certain disputed issues. Tax years 2016-2018 are currently under audit. Tax years 2019-2022 are open but not under audit. All other tax years are closed. In addition to the open audit years in the U.S., we have open audit years in certain major international tax jurisdictions dating back to 2011. For additional information, see Note 5D in our 2021 Form 10-K. C. Tax Provision/(Benefit) on Other Comprehensive Income/(Loss) Components of Tax provision/(benefit) on other comprehensive income/(loss) include: Three Months Ended (MILLIONS) April 3, April 4, Foreign currency translation adjustments, net (a) $ (72) $ 21 Unrealized holding gains/(losses) on derivative financial instruments, net 32 59 Reclassification adjustments for (gains)/losses included in net income (22) 34 10 93 Unrealized holding gains/(losses) on available-for-sale securities, net (17) 10 Reclassification adjustments for (gains)/losses included in net income 29 (30) 12 (20) Reclassification adjustments related to amortization of prior service costs and other, net (9) (10) Reclassification adjustments related to curtailments of prior service costs and other, net (2) — Other — — (11) (10) Tax provision/(benefit) on other comprehensive income/(loss) $ (60) $ 84 (a) Taxes are not provided for foreign currency translation adjustments relating to investments in international subsidiaries that we intend to hold indefinitely.

Accumulated Other Comprehensive

Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests	3 Months Ended
	Apr. 03, 2022
Equity [Abstract]
Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests	Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests The following summarizes the changes, net of tax, in Accumulated other comprehensive loss : Net Unrealized Gains/(Losses) Benefit Plans (MILLIONS) Foreign Currency Translation Adjustments Derivative Financial Instruments Available-For-Sale Securities Prior Service (Costs)/Credits and Other Accumulated Other Comprehensive Income/(Loss) Balance, December 31, 2021 $ (6,172) $ 119 $ (220) $ 377 $ (5,897) Other comprehensive income/(loss) (a) (291) (20) 87 (36) (260) Balance, April 3, 2022 $ (6,463) $ 99 $ (133) $ 341 $ (6,157) (a) Amounts do not include foreign currency translation adjustments attributable to noncontrolling interests. Foreign currency translation adjustments include net losses related to our equity method investment in the Consumer Healthcare JV (see Note 2C ) and the impact of our net investment hedging program.

Financial Instruments

Financial Instruments	3 Months Ended
	Apr. 03, 2022
Fair Value Disclosures [Abstract]
Financial Instruments	Financial Instruments A. Fair Value Measurements Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis and Fair Value Hierarchy, using a Market Approach: April 3, 2022 December 31, 2021 (MILLIONS) Total Level 1 Level 2 Total Level 1 Level 2 Financial assets: Short-term investments Classified as equity securities with readily determinable fair values: Money market funds $ 2,759 $ — $ 2,759 $ 5,365 $ — $ 5,365 Classified as available-for-sale debt securities: Government and agency—non-U.S. 14,548 — 14,548 17,318 — 17,318 Government and agency—U.S. 1,830 — 1,830 4,050 — 4,050 Corporate and other 958 — 958 647 — 647 17,337 — 17,337 22,014 — 22,014 Total short-term investments 20,096 — 20,096 27,379 — 27,379 Other current assets Derivative assets: Interest rate contracts 5 — 5 4 — 4 Foreign exchange contracts 832 — 832 704 — 704 Total other current assets 837 — 837 709 — 709 Long-term investments Classified as equity securities with readily determinable fair values (a) 3,486 3,470 15 3,876 3,849 27 Classified as available-for-sale debt securities: Government and agency—non-U.S. 519 — 519 465 — 465 Government and agency—U.S. 1 — 1 6 — 6 Corporate and other 49 — 49 50 — 50 569 — 569 521 — 521 Total long-term investments 4,055 3,470 584 4,397 3,849 548 Other noncurrent assets Derivative assets: Interest rate contracts — — — 16 — 16 Foreign exchange contracts 267 — 267 242 — 242 Total derivative assets 267 — 267 259 — 259 Insurance contracts (b) 765 — 765 808 — 808 Total other noncurrent assets 1,032 — 1,032 1,067 — 1,067 Total assets $ 26,020 $ 3,470 $ 22,550 $ 33,552 $ 3,849 $ 29,703 Financial liabilities: Other current liabilities Derivative liabilities: Foreign exchange contracts $ 330 $ — $ 330 $ 476 $ — $ 476 Total other current liabilities 330 — 330 476 — 476 Other noncurrent liabilities Derivative liabilities: Interest rate contracts 140 — 140 — — — Foreign exchange contracts 460 — 460 405 — 405 Total other noncurrent liabilities 600 — 600 405 — 405 Total liabilities $ 930 $ — $ 930 $ 881 $ — $ 881 (a) Long-term equity securities of $155 million as of April 3, 2022 and $194 million as of December 31, 2021 were held in restricted trusts for U.S. non-qualified employee benefit plans. (b) Includes life insurance policies held in restricted trusts for U.S. non-qualified employee benefit plans. The underlying invested assets in these contracts are marketable securities, which are carried at fair value, with changes in fair value recognized in Other (income)/deductions—net (see Note 4 ). Financial Assets and Liabilities Not Measured at Fair Value on a Recurring Basis–– The carrying value of Long-term debt, excluding the current portion was $36 billion as of April 3, 2022 and $36 billion as of December 31, 2021. The estimated fair value of such debt, using a market approach and Level 2 inputs, was $38 billion as of April 3, 2022 and $42 billion as of December 31, 2021. The differences between the estimated fair values and carrying values of held-to-maturity debt securities, private equity securities, long-term receivables and short-term borrowings not measured at fair value on a recurring basis were not significant as of April 3, 2022 and December 31, 2021. The fair value measurements of our held-to-maturity debt securities and short-term borrowings are based on Level 2 inputs. The fair value measurements of our long-term receivables and private equity securities are based on Level 3 inputs. B. Investments Total Short-Term, Long-Term and Equity-Method Investments The following summarizes our investments by classification type: (MILLIONS) April 3, 2022 December 31, 2021 Short-term investments Equity securities with readily determinable fair values (a) $ 2,759 $ 5,365 Available-for-sale debt securities 17,337 22,014 Held-to-maturity debt securities 1,331 1,746 Total Short-term investments $ 21,427 $ 29,125 Long-term investments Equity securities with readily determinable fair values $ 3,486 $ 3,876 Available-for-sale debt securities 569 521 Held-to-maturity debt securities 41 34 Private equity securities at cost (b) 647 623 Total Long-term investments $ 4,742 $ 5,054 Equity-method investments 15,995 16,472 Total long-term investments and equity-method investments $ 20,737 $ 21,526 Held-to-maturity cash equivalents $ 458 $ 268 (a) As of April 3, 2022 and December 31, 2021, includes money market funds primarily invested in U.S. Treasury and government debt. (b) Represent investments in the life sciences sector. Debt Securities At April 3, 2022, our investment portfolio consisted of debt securities issued across diverse governments, corporate and financial institutions, which are investment-grade. The contractual or estimated maturities, are as follows: April 3, 2022 December 31, 2021 Gross Unrealized Maturities (in Years) Gross Unrealized (MILLIONS) Amortized Cost Gains Losses Fair Value Within 1 Over 1 Over 5 Amortized Cost Gains Losses Fair Value Available-for-sale debt securities Government and agency –– non-U.S. $ 15,217 $ 8 $ (158) $ 15,067 $ 14,548 $ 519 $ — $ 18,032 $ 13 $ (263) $ 17,783 Government and agency––U.S. 1,832 — (1) 1,831 1,830 1 — 4,056 — (1) 4,055 Corporate and other 1,009 — (1) 1,008 958 49 — 698 — (1) 697 Held-to-maturity debt securities Time deposits and other 1,015 — — 1,015 979 25 11 947 — — 947 Government and agency –– non-U.S. 814 — — 814 809 4 1 1,102 — — 1,102 Total debt securities $ 19,887 $ 8 $ (160) $ 19,735 $ 19,125 $ 598 $ 12 $ 24,835 $ 14 $ (265) $ 24,584 Any expected credit losses to these portfolios would be immaterial to our financial statements. Equity Securities The following presents the calculation of the portion of unrealized (gains)/losses that relates to equity securities, excluding equity-method investments, held at the reporting date: Three Months Ended (MILLIONS) April 3, April 4, Net (gains)/losses recognized during the period on equity securities (a) $ 699 $ (401) Less: Net (gains)/losses recognized during the period on equity securities sold during the period (11) (28) Net unrealized (gains)/losses during the reporting period on equity securities still held at the reporting date (b) $ 710 $ (372) (a) Reported in Other (income)/deductions –– net. See Note 4 . (b) Included in net unrealized (gains)/losses are observable price changes on equity securities without readily determinable fair values. As of April 3, 2022, there were cumulative impairments and downward adjustments of $110 million and upward adjustments of $167 million. Impairments, downward and upward adjustments were not significant in the first quarters of 2022 and 2021. C. Short-Term Borrowings Short-term borrowings include: (MILLIONS) April 3, December 31, 2021 Current portion of long-term debt, principal amount $ 251 $ 1,636 Other short-term borrowings, principal amount (a) 385 605 Total short-term borrowings, principal amount 636 2,241 Net fair value adjustments related to hedging and purchase accounting 9 — Total Short-term borrowings, including current portion of long-term debt , carried at historical proceeds, as adjusted $ 645 $ 2,241 (a) Primarily includes cash collateral. See Note 7F . D. Long-Term Debt The following summarizes the aggregate principal amount of our senior unsecured long-term debt, and adjustments to report our aggregate long-term debt: (MILLIONS) April 3, December 31, 2021 Total long-term debt, principal amount $ 34,603 $ 34,948 Net fair value adjustments related to hedging and purchase accounting 1,240 1,438 Net unamortized discounts, premiums and debt issuance costs (190) (195) Other long-term debt 3 4 Total long-term debt, carried at historical proceeds, as adjusted $ 35,656 $ 36,195 Current portion of long-term debt, carried at historical proceeds, as adjusted (not included above) $ 260 $ 1,636 E. Derivative Financial Instruments and Hedging Activities Foreign Exchange Risk–– A significant portion of our revenues, earnings and net investments in foreign affiliates is exposed to changes in foreign exchange rates. Where foreign exchange risk is not offset by other exposures, we manage our foreign exchange risk principally through the use of derivative financial instruments and foreign currency debt. These financial instruments serve to mitigate the impact on net income as a result of remeasurement into another currency, or against the impact of translation into U.S. dollars of certain foreign exchange-denominated transactions. The derivative financial instruments primarily hedge or offset exposures in the euro, U.K. pound, Japanese yen and Canadian dollar, and include a portion of our forecasted foreign exchange-denominated intercompany inventory sales hedged up to two years. We may seek to protect against possible declines in the reported net investments of our foreign business entities. Interest Rate Risk–– Our interest-bearing investments and borrowings are subject to interest rate risk. Depending on market conditions, we may change the profile of our outstanding debt or investments by entering into derivative financial instruments like interest rate swaps, either to hedge or offset the exposure to changes in the fair value of hedged items with fixed interest rates, or to convert variable rate debt or investments to fixed rates. The derivative financial instruments primarily hedge U.S. dollar fixed-rate debt. The following summarizes the fair value of the derivative financial instruments and notional amounts (including those reported as part of discontinued operations): April 3, 2022 December 31, 2021 Fair Value Fair Value (MILLIONS) Notional Asset Liability Notional Asset Liability Derivatives designated as hedging instruments : Foreign exchange contracts (a) $ 29,833 $ 899 $ 647 $ 29,576 $ 787 $ 717 Interest rate contracts 2,250 5 140 2,250 21 — 904 787 808 717 Derivatives not designated as hedging instruments : Foreign exchange contracts $ 22,009 200 143 $ 21,419 160 164 Total $ 1,104 $ 930 $ 968 $ 881 (a) The notional amount of outstanding foreign exchange contracts hedging our intercompany forecasted inventory sales was $4.7 billion as of April 3, 2022 and $4.8 billion as of December 31, 2021. The following summarizes information about the gains/(losses) incurred to hedge or offset operational foreign exchange or interest rate risk exposures (including those reported as part of discontinued operations): Gains/(Losses) (a) Gains/(Losses) (a) Gains/(Losses) Reclassified from OCI into OID and COS (a) Three Months Ended (MILLIONS) April 3, April. 4, April 3, April. 4, April 3, April. 4, Derivative Financial Instruments in Cash Flow Hedge Relationships: Foreign exchange contracts (b) $ — $ — $ 187 $ 202 $ 195 $ (268) Amount excluded from effectiveness testing and amortized into earnings (c) — — 16 12 18 9 Derivative Financial Instruments in Fair Value Hedge Relationships: Interest rate contracts (156) (26) — — — — Hedged item 156 26 — — — — Derivative Financial Instruments in Net Investment Hedge Relationships: Foreign exchange contracts — — 259 154 — — Amount excluded from effectiveness testing and amortized into earnings (c) — — (74) (1) 30 29 Non-Derivative Financial Instruments in Net Investment Hedge Relationships: (d) Foreign currency short-term borrowings — — 26 38 — — Foreign currency long-term debt — — 23 56 — — Derivative Financial Instruments Not Designated as Hedges: Foreign exchange contracts (19) 42 — — — — $ (19) $ 42 $ 436 $ 460 $ 243 $ (230) (a) OID = Other (income)/deductions—net, included in Other (income)/deductions—net in the condensed consolidated statements of income . COS = Cost of Sales, included in Cost of sales in the condensed consolidated statements of income. OCI = Other comprehensive income/(loss), included in the condensed consolidated statements of comprehensive income . (b) The amounts reclassified from OCI into COS were: • a net gain of $34 million in the first quarter of 2022; and • a net loss of $45 million in the first quarter of 2021. The remaining amounts were reclassified from OCI into OID. Based on quarter-end foreign exchange rates that are subject to change, we expect to reclassify a pre-tax gain of $332 million within the next 12 months into income . The maximum length of time over which we are hedging our exposure to the variability in future foreign exchange cash flows is approximately 21 years and relates to foreign currency debt. (c) The amounts reclassified from OCI were reclassified into OID. (d) Short-term borrowings and long-term debt include foreign currency borrowings which are used in net investment hedges. The short-term borrowings’ carrying value as of December 31, 2021 was $1.1 billion. The long-term debt carrying values as of April 3, 2022 and December 31, 2021 were $821 million and $844 million, respectively. The following summarizes cumulative basis adjustments to our debt in fair value hedges: April 3, 2022 December 31, 2021 Cumulative Amount of Fair Value Hedging Adjustment Increase/(Decrease) to Cumulative Amount of Fair Value Hedging Adjustment Increase/(Decrease) to (MILLIONS) Carrying Amount of Hedged Assets/Liabilities (a) Active Hedging Relationships Discontinued Hedging Relationships Carrying Amount of Hedged Assets/Liabilities (a) Active Hedging Relationships Discontinued Hedging Relationships Short-term borrowings, including current portion of long-term debt $ — $ — $ 4 $ — $ — $ — Long-term debt $ 2,234 $ (140) $ 1,124 $ 2,233 $ 16 $ 1,154 (a) Carrying amounts exclude the cumulative amount of fair value hedging adjustments. F. Credit Risk A significant portion of our trade accounts receivable balances are due from wholesalers and governments. For additional information on our trade accounts receivables with significant customers, see Note 13C below and Note 17C in our 2021 Form 10-K. As of April 3, 2022, the largest investment exposures in our portfolio represent primarily sovereign debt instruments issued by Canada, Japan, U.S., France, Germany, U.K., Switzerland, Austria and the Netherlands. With respect to our derivative financial instrument agreements with financial institutions, we do not expect to incur a significant loss from failure of any counterparty. Derivative financial instruments are executed under International Swaps and Derivatives Association master agreements with credit-support annexes that contain zero threshold provisions requiring collateral to be exchanged daily depending on levels of exposure. As a result, there are no significant concentrations of credit risk with any individual financial institution. As of April 3, 2022, the aggregate fair value of these derivative financial instruments that are in a net payable position was $568 million, for which we have posted collateral of $526 million with a corresponding amount reported in Short-term investments . As of April 3, 2022, the aggregate fair value of our derivative financial instruments that are in a net receivable position was $532 million, for which we have received collateral of $341 million with a corresponding amount reported in Short-term borrowings, including current portion of long-term debt.

Other Financial Information

Other Financial Information	3 Months Ended
	Apr. 03, 2022
Other Financial Information [Abstract]
Other Financial Information	Other Financial Information A. Inventories The following summarizes the components of Inventories : (MILLIONS) April 3, December 31, 2021 Finished goods $ 3,633 $ 3,641 Work-in-process 4,843 4,424 Raw materials and supplies 1,502 994 Inventories (a) $ 9,979 $ 9,059 Noncurrent inventories not included above (b) $ 894 $ 939 (a) The change from December 31, 2021 reflects increases for Paxlovid and Comirnaty, as well as increases for certain products mainly for network strategy and supply recovery, partially offset by decreases due to market demand. (b) Included in Other noncurrent assets . There are no recoverability issues for these amounts. B. Other Current Liabilities

Identifiable Intangible Assets

Identifiable Intangible Assets	3 Months Ended
	Apr. 03, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Identifiable Intangible Assets	Identifiable Intangible Assets A. Identifiable Intangible Assets The following summarizes the components of Identifiable intangible assets : April 3, 2022 December 31, 2021 (MILLIONS) Gross Accumulated Identifiable Gross Accumulated Identifiable Finite-lived intangible assets Developed technology rights $ 73,212 $ (54,397) $ 18,815 $ 73,346 $ (53,732) $ 19,614 Brands 922 (816) 106 922 (807) 115 Licensing agreements and other 2,302 (1,329) 973 2,284 (1,299) 985 76,436 (56,542) 19,894 76,552 (55,838) 20,714 Indefinite-lived intangible assets Brands 827 827 827 827 IPR&D (a) 8,122 8,122 3,092 3,092 Licensing agreements and other (a) 973 973 513 513 9,922 9,922 4,432 4,432 Identifiable intangible assets (a), (b) $ 86,358 $ (56,542) $ 29,816 $ 80,984 $ (55,838) $ 25,146 (a) The increase in the gross carrying amounts mainly reflect the impact of the acquisition of Arena. See Note 2A . (b) The increase is primarily due to the acquisition of Arena, partially offset by amortization expense. B. Goodwill The following summarizes the changes in the carrying amount of Goodwill : (MILLIONS) Total (a) Balance, January 1, 2022 $ 49,208 Additions (b) 1,023 Other (c) (21) Balance, April 3, 2022 $ 50,211 (a) All goodwill is assigned within the Biopharma reportable segment. (b) Additions relate to our acquisition of Arena. See Note 2A . (c) Other represents the impact of foreign exchange.

Pension and Postretirement Bene

Pension and Postretirement Benefit Plans	3 Months Ended
	Apr. 03, 2022
Retirement Benefits [Abstract]
Pension and Postretirement Benefit Plans	Pension and Postretirement Benefit Plans The following summarizes the components of net periodic benefit cost/(credit): Pension Plans U.S. International Postretirement Three Months Ended (MILLIONS) April 3, April. 4, April 3, April. 4, April 3, April. 4, Service cost $ — $ — $ 30 $ 33 $ 7 $ 9 Interest cost 118 113 42 36 7 7 Expected return on plan assets (245) (261) (79) (82) (12) (10) Amortization of prior service credits — (1) — — (36) (39) Actuarial (gains)/losses (a) (65) (47) — — — — Curtailments — — — — (13) — Special termination benefits 6 7 — — — 1 Net periodic benefit cost/(credit) reported in income $ (186) $ (187) $ (8) $ (12) $ (46) $ (32) (a) Mainly reflects interim actuarial remeasurement gains in 2022, primarily due to an increase in the discount rate. The components of net periodic benefit cost/(credit) other than the service cost component are primarily included in Other (income)/deductions––net (see Note 4 ).

Earnings Per Common Share Attri

Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders	3 Months Ended
	Apr. 03, 2022
Earnings Per Share [Abstract]
Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders	Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders The following presents the detailed calculation of EPS : Three Months Ended (MILLIONS) April 3, April 4, EPS Numerator––Basic Income from continuing operations attributable to Pfizer Inc. common shareholders $ 7,872 $ 4,876 Discontinued operations––net of tax (9) 1 Net income attributable to Pfizer Inc. common shareholders $ 7,864 $ 4,877 EPS Numerator––Diluted Income from continuing operations attributable to Pfizer Inc. common shareholders and assumed conversions $ 7,872 $ 4,876 Discontinued operations––net of tax, attributable to Pfizer Inc. common shareholders and assumed conversions (9) 1 Net income attributable to Pfizer Inc. common shareholders and assumed conversions $ 7,864 $ 4,877 EPS Denominator Weighted-average number of common shares outstanding––Basic 5,617 5,584 Common-share equivalents: stock options and stock issuable under employee compensation plans 141 78 Weighted-average number of common shares outstanding––Diluted 5,758 5,662 Anti-dilutive common stock equivalents (a) — 2 (a) These common stock equivalents were outstanding for the periods presented, but were not included in the computation of diluted EPS for those periods because their inclusion would have had an anti-dilutive effect.

Contingencies and Certain Commi

Contingencies and Certain Commitments	3 Months Ended
	Apr. 03, 2022
Commitments and Contingencies Disclosure [Abstract]
Contingencies and Certain Commitments	Contingencies and Certain Commitments We and certain of our subsidiaries are subject to numerous contingencies arising in the ordinary course of business, including tax and legal contingencies. The following outlines our legal contingencies. For a discussion of our tax contingencies, see Note 5B. A. Legal Proceedings Our legal contingencies include, but are not limited to, the following: • Patent litigation, which typically involves challenges to the coverage and/or validity of patents on various products, processes or dosage forms. An adverse outcome could result in loss of patent protection for a product, a significant loss of revenues from a product or impairment of the value of associated assets. We are the plaintiff in the majority of these actions. • Product liability and other product-related litigation related to current or former products, which can include personal injury, consumer, off-label promotion, securities, antitrust and breach of contract claims, among others, and often involves highly complex issues relating to medical causation, label warnings and reliance on those warnings, scientific evidence and findings, actual, provable injury and other matters. • Commercial and other asserted or unasserted matters, which can include acquisition-, licensing-, intellectual property-, collaboration- or co-promotion-related and product-pricing claims and environmental claims and proceedings, can involve complexities that will vary from matter to matter. • Government investigations, which often are related to the extensive regulation of pharmaceutical companies by national, state and local government agencies in the U.S. and in other jurisdictions. Certain of these contingencies could result in increased expenses and/or losses, including damages, royalty payments, fines and/or civil penalties, which could be substantial, and/or criminal charges. We believe that our claims and defenses in matters in which we are a defendant are substantial, but litigation is inherently unpredictable and excessive verdicts do occur. We do not believe that any of these matters will have a material adverse effect on our financial position. However, we could incur judgments, enter into settlements or revise our expectations regarding the outcome of matters, which could have a material adverse effect on our results of operations and/or our cash flows in the period in which the amounts are accrued or paid. We have accrued for losses that are both probable and reasonably estimable. Substantially all of our contingencies are subject to significant uncertainties and, therefore, determining the likelihood of a loss and/or the measurement of any loss can be complex. Consequently, we are unable to estimate the range of reasonably possible loss in excess of amounts accrued. Our assessments, which result from a complex series of judgments about future events and uncertainties, are based on estimates and assumptions that have been deemed reasonable by management, but that may prove to be incomplete or inaccurate, and unanticipated events and circumstances may occur that might cause us to change those estimates and assumptions. Amounts recorded for legal and environmental contingencies can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions. For proceedings under environmental laws to which a governmental authority is a party, we have adopted a disclosure threshold of $1 million in potential or actual governmental monetary sanctions. The principal pending matters to which we are a party are discussed below. In determining whether a pending matter is a principal matter, we consider both quantitative and qualitative factors to assess materiality, such as, among others, the amount of damages and the nature of other relief sought, if specified; our view of the merits of the claims and of the strength of our defenses; whether the action purports to be, or is, a class action and, if not certified, our view of the likelihood that a class will be certified by the court; the jurisdiction in which the proceeding is pending; whether related actions have been transferred to multidistrict litigation; any experience that we or, to our knowledge, other companies have had in similar proceedings; whether disclosure of the action would be important to a reader of our financial statements, including whether disclosure might change a reader’s judgment about our financial statements in light of all of the information that is available to the reader; the potential impact of the proceeding on our reputation; and the extent of public interest in the matter. In addition, with respect to patent matters in which we are the plaintiff, we consider, among other things, the financial significance of the product protected by the patent(s) at issue. Some of the matters discussed below include those which management believes that the likelihood of possible loss in excess of amounts accrued is remote. A1. Legal Proceedings––Patent Litigation We are involved in suits relating to our patents, including but not limited to, those discussed below. Most involve claims by generic drug manufacturers that patents covering our products (or those of our collaboration/licensing partners to which we have licenses or co-promotion rights and to which we may or may not be a party), processes or dosage forms are invalid and/or do not cover the product of the generic drug manufacturer. Also, counterclaims, as well as various independent actions, have been filed alleging that our assertions of, or attempts to enforce, patent rights with respect to certain products constitute unfair competition and/or violations of antitrust laws. In addition to the challenges to the U.S. patents that are discussed below, patent rights to certain of our products or those of our collaboration/licensing partners are being challenged in various other jurisdictions. Some of our collaboration or licensing partners face challenges to the validity of their patent rights in non-U.S. jurisdictions. For example, in April 2022, the U.K. High Court issued a judgment finding invalid a BMS patent related to Eliquis due to expire in 2026. BMS will seek permission to appeal the High Court’s decision. Additional challenges remain pending in other jurisdictions. We are also party to patent damages suits in various jurisdictions pursuant to which generic drug manufacturers, payers, governments or other parties are seeking damages from us for allegedly causing delay of generic entry. We also are often involved in other proceedings, such as inter partes review, post-grant review, re-examination or opposition proceedings, before the U.S. Patent and Trademark Office, the European Patent Office, or other foreign counterparts relating to our intellectual property or the intellectual property rights of others. Also, if one of our patents is found to be invalid by such proceedings, generic or competitive products could be introduced into the market resulting in the erosion of sales of our existing products. For example, several of the patents in our pneumococcal vaccine portfolio were challenged in inter partes review and post-grant review proceedings in the U.S. In 2017, the Patent Trial and Appeal Board (PTAB) initiated proceedings with respect to two of our pneumococcal vaccine patents. However, the PTAB declined to initiate proceedings as to two other pneumococcal vaccine patents; those two patents, and one other patent, were challenged in federal court in Delaware. In September 2021, Pfizer and a challenger entered into a settlement and license agreement, resolving all worldwide legal proceedings involving that challenger, related to our pneumococcal vaccine patents. Other challenges to pneumococcal vaccine patents remain pending at the PTAB and outside the U.S. The invalidation of any of the patents in our pneumococcal portfolio could potentially allow additional competitor vaccines into the marketplace. In the event that any of the patents are found valid and infringed, a competitor’s vaccine might be prohibited from entering the market or a competitor might be required to pay us a royalty. We are also subject to patent litigation pursuant to which one or more third parties seek damages and/or injunctive relief to compensate for alleged infringement of its patents by our commercial or other activities. For example, our Hospira subsidiaries are involved in patent and patent-related disputes over their attempts to bring generic pharmaceutical products to market. If one of our marketed products is found to infringe valid patent rights of a third party, such third party may be awarded significant damages or royalty payments, or we may be prevented from further sales of that product. Such damages may be enhanced as much as three-fold if we or one of our subsidiaries is found to have willfully infringed valid patent rights of a third party. Actions In Which We Are The Plaintiff EpiPen In 2010, King, which we acquired in 2011 and is a wholly-owned subsidiary, brought a patent-infringement action against Sandoz in the U.S. District Court for the District of New Jersey in connection with Sandoz’s abbreviated new drug application (ANDA) filed with the FDA seeking approval to market an epinephrine injectable product. Sandoz is challenging patents, which expire in 2025, covering the next-generation autoinjector for use with epinephrine that is sold under the EpiPen brand name. Xeljanz (tofacitinib) Beginning in 2017, we brought patent-infringement actions against several generic manufacturers that filed separate ANDAs with the FDA seeking approval to market their generic versions of tofacitinib tablets in one or both of 5 mg and 10 mg dosage strengths, and in both immediate and extended release forms. To date, we have settled actions with several manufacturers on terms not material to us. The remaining actions continue in the U.S. District Court for the District of Delaware as described below. In January 2021, we brought a separate patent-infringement action against Aurobindo Pharma Limited (Aurobindo) asserting the infringement and validity of the patent covering the active ingredient expiring in December 2025 and the patent covering a polymorphic form of tofacitinib expiring in 2023, which Aurobindo challenged in its ANDA seeking approval to market a generic version of tofacitinib 5 mg and 10 mg tablets. In May 2022, we settled our action against Aurobindo on terms not material to us. In October 2021, we brought a separate patent-infringement action against Sinotherapeutics Inc. (Sinotherapeutics) asserting the infringement and validity of our patent covering extended release formulations of tofacitinib that was challenged by Sinotherapeutics in its ANDA seeking approval to market a generic version of tofacitinib 11 mg extended release tablets. In February 2022, we brought a separate patent-infringement action against Teva Pharmaceuticals USA, Inc. (Teva) asserting the infringement and validity of our patent covering extended release formulations of tofacitinib that was challenged by Teva in its ANDA seeking approval to market a generic version of tofacitinib 22 mg extended release tablets. In April 2022, we settled our action against Teva on terms not material to us. In February 2022, we brought a separate patent-infringement action against Slayback Pharma LLC (Slayback) asserting the infringement and validity of our compound patent covering the active ingredient that was challenged by Slayback in its ANDA seeking approval to market a generic version of tofacitinib oral solution 1 mg/mL. Inlyta (axitinib) In 2019, Glenmark Pharmaceuticals Ltd. (Glenmark) notified us that it had filed an ANDA with the FDA seeking approval to market a generic version of Inlyta. Glenmark asserts the invalidity and non-infringement of the crystalline form patent for Inlyta that expires in 2030. In 2019, we filed suit against Glenmark in the U.S. District Court for the District of Delaware, asserting the validity and infringement of the crystalline form patent for Inlyta. Ibrance (palbociclib) Beginning in September 2020, we received correspondence from several generic companies notifying us that they would seek approval to market generic versions of Ibrance capsules. The generic companies assert the invalidity and non-infringement of our crystalline form patent which expires in 2034. Beginning in October 2020, we brought patent infringement actions against each of these generic companies in various federal courts, asserting the validity and infringement of the crystalline form patent. We have settled with certain of these generic companies on terms not material to us, and we dismissed the patent infringement actions against certain other generic companies. Beginning in January 2021, several generic companies notified us that they had filed ANDAs with the FDA seeking approval to market generic versions of Ibrance tablets. The generic companies are challenging some or all of the following patents: (i) the composition of matter patent expiring in 2027; (ii) the composition of matter patent expiring in 2023; (iii) the method of use patent expiring in 2023; (iv) the crystalline form patent expiring in 2034; and (v) a tablet formulation patent expiring in 2036. We brought patent infringement actions against each of the generic filers in various federal courts, asserting the validity and infringement of the patents challenged by the generic companies. We have settled with one of these generic companies on terms not material to us, and we dismissed the patent infringement actions relating to the crystalline form of patent against certain other generic companies. Eucrisa Beginning in September 2021, several generic companies notified us that they had filed ANDAs with the FDA seeking approval to market generic versions of Eucrisa. The companies assert the invalidity and non-infringement of a composition of matter patent expiring in 2026, two method of use patents expiring in 2027, and one other method of use patent expiring in 2030. In September 2021, we brought patent infringement actions against the generic filers in the U.S. District Court for the District of Delaware, asserting the validity and infringement of the patents challenged by the generic companies. Action in Which We are the Defendant Comirnaty In March 2022, Alnylam Pharmaceuticals, Inc. filed a complaint in the U.S. District Court for the District of Delaware against Pfizer and Pharmacia & Upjohn Co. LLC, our wholly owned subsidiary, alleging that Comirnaty infringes U.S. Patent No. 11,246,933, which was issued in February 2022, and seeking unspecified monetary damages. Matter Involving Our Collaboration/Licensing Partners Eliquis In 2017, twenty-five generic companies sent BMS Paragraph-IV certification letters informing BMS that they had filed ANDAs seeking approval of generic versions of Eliquis, challenging the validity and infringement of one or more of the three patents listed in the Orange Book for Eliquis. One of the patents expired in December 2019 and the remaining patents currently are set to expire in 2026 and 2031. Eliquis has been jointly developed and is being commercialized by BMS and Pfizer. BMS and Pfizer filed patent-infringement actions against all generic filers in the U.S. District Court for the District of Delaware and the U.S. District Court for the District of West Virginia, asserting that each of the generic companies’ proposed products would infringe each of the patent(s) that each generic filer challenged. Some generic filers challenged only the 2031 patent, some challenged both the 2031 and 2026 patent, and one generic company challenged all three patents. In August 2020, the U.S. District Court for the District of Delaware ruled that both the 2026 patent and the 2031 patent are valid and infringed by the proposed generic products. In August and September 2020, the generic filers appealed the District Court’s decision to the U.S. Court of Appeals for the Federal Circuit. Prior to the August 2020 ruling, we and BMS settled with certain of the companies on terms not material to us, and we and BMS may settle with other generic companies in the future. In September 2021, the U.S. Court of Appeals for the Federal Circuit affirmed the District Court’s decision. A2. Legal Proceedings––Product Litigation We are defendants in numerous cases, including but not limited to those discussed below, related to our pharmaceutical and other products. Plaintiffs in these cases seek damages and other relief on various grounds for alleged personal injury and economic loss. Asbestos Between 1967 and 1982, Warner-Lambert owned American Optical Corporation (American Optical), which manufactured and sold respiratory protective devices and asbestos safety clothing. In connection with the sale of American Optical in 1982, Warner-Lambert agreed to indemnify the purchaser for certain liabilities, including certain asbestos-related and other claims. Warner-Lambert was acquired by Pfizer in 2000 and is a wholly owned subsidiary of Pfizer. Warner-Lambert is actively engaged in the defense of, and will continue to explore various means of resolving, these claims. Numerous lawsuits against American Optical, Pfizer and certain of its previously owned subsidiaries are pending in various federal and state courts seeking damages for alleged personal injury from exposure to products allegedly containing asbestos and other allegedly hazardous materials sold by Pfizer and certain of its previously owned subsidiaries. There also are a small number of lawsuits pending in various federal and state courts seeking damages for alleged exposure to asbestos in facilities owned or formerly owned by Pfizer or its subsidiaries. Effexor Beginning in 2011, actions, including purported class actions, were filed in various federal courts against Wyeth and, in certain of the actions, affiliates of Wyeth and certain other defendants relating to Effexor XR, which is the extended-release formulation of Effexor. The plaintiffs in each of the class actions seek to represent a class consisting of all persons in the U.S. and its territories who directly purchased, indirectly purchased or reimbursed patients for the purchase of Effexor XR or generic Effexor XR from any of the defendants from June 14, 2008 until the time the defendants’ allegedly unlawful conduct ceased. The plaintiffs in all of the actions allege delay in the launch of generic Effexor XR in the U.S. and its territories, in violation of federal antitrust laws and, in certain of the actions, the antitrust, consumer protection and various other laws of certain states, as the result of Wyeth fraudulently obtaining and improperly listing certain patents for Effexor XR in the Orange Book, enforcing certain patents for Effexor XR and entering into a litigation settlement agreement with a generic drug manufacturer with respect to Effexor XR. Each of the plaintiffs seeks treble damages (for itself in the individual actions or on behalf of the putative class in the purported class actions) for alleged price overcharges for Effexor XR or generic Effexor XR in the U.S. and its territories since June 14, 2008. All of these actions have been consolidated in the U.S. District Court for the District of New Jersey. In 2014, the District Court dismissed the direct purchaser plaintiffs’ claims based on the litigation settlement agreement, but declined to dismiss the other direct purchaser plaintiff claims. In 2015, the District Court entered partial final judgments as to all settlement agreement claims, including those asserted by direct purchasers and end-payer plaintiffs, which plaintiffs appealed to the U.S. Court of Appeals for the Third Circuit. In 2017, the U.S. Court of Appeals for the Third Circuit reversed the District Court’s decisions and remanded the claims to the District Court. Lipitor Beginning in 2011, purported class actions relating to Lipitor were filed in various federal courts against, among others, Pfizer, certain Pfizer affiliates, and, in most of the actions, Ranbaxy Laboratories Ltd. (Ranbaxy) and certain Ranbaxy affiliates. The plaintiffs in these various actions seek to represent nationwide, multi-state or statewide classes consisting of persons or entities who directly purchased, indirectly purchased or reimbursed patients for the purchase of Lipitor (or, in certain of the actions, generic Lipitor) from any of the defendants from March 2010 until the cessation of the defendants’ allegedly unlawful conduct (the Class Period). The plaintiffs allege delay in the launch of generic Lipitor, in violation of federal antitrust laws and/or state antitrust, consumer protection and various other laws, resulting from (i) the 2008 agreement pursuant to which Pfizer and Ranbaxy settled certain patent litigation involving Lipitor and Pfizer granted Ranbaxy a license to sell a generic version of Lipitor in various markets beginning on varying dates, and (ii) in certain of the actions, the procurement and/or enforcement of certain patents for Lipitor. Each of the actions seeks, among other things, treble damages on behalf of the putative class for alleged price overcharges for Lipitor (or, in certain of the actions, generic Lipitor) during the Class Period. In addition, individual actions have been filed against Pfizer, Ranbaxy and certain of their affiliates, among others, that assert claims and seek relief for the plaintiffs that are substantially similar to the claims asserted and the relief sought in the purported class actions described above. These various actions have been consolidated for pre-trial proceedings in a Multi-District Litigation in the U.S. District Court for the District of New Jersey. In September 2013 and 2014, the District Court dismissed with prejudice the claims of the direct purchasers. In October and November 2014, the District Court dismissed with prejudice the claims of all other Multi-District Litigation plaintiffs. All plaintiffs have appealed the District Court’s orders dismissing their claims with prejudice to the U.S. Court of Appeals for the Third Circuit. In addition, the direct purchaser class plaintiffs appealed the order denying their motion to amend the judgment and for leave to amend their complaint to the Court of Appeals. In 2017, the Court of Appeals reversed the District Court’s decisions and remanded the claims to the District Court. Also, in 2013, the State of West Virginia filed an action in West Virginia state court against Pfizer and Ranbaxy, among others, that asserts claims and seeks relief on behalf of the State of West Virginia and residents of that state that are substantially similar to the claims asserted and the relief sought in the purported class actions described above. EpiPen (Direct Purchaser) In February 2020, a lawsuit was filed in the U.S. District Court for the District of Kansas against Pfizer, its current and former affiliates King and Meridian, and various Mylan entities, on behalf of a purported U.S. nationwide class of direct purchaser plaintiffs who purchased EpiPen devices directly from the defendants. Plaintiffs in this action generally allege that Pfizer and Mylan conspired to delay market entry of generic EpiPen through the settlement of patent litigation regarding EpiPen, and thereby delayed market entry of generic EpiPen in violation of federal antitrust law. Plaintiffs seek treble damages for alleged overcharges for EpiPen since 2011. In July 2021, the District Court granted defendants’ motion to dismiss the direct purchaser complaint, without prejudice. In September 2021, plaintiffs filed an amended complaint. Nexium 24HR and Protonix A number of individual and multi-plaintiff lawsuits have been filed against Pfizer, certain of its subsidiaries and/or other pharmaceutical manufacturers in various federal and state courts alleging that the plaintiffs developed kidney-related injuries purportedly as a result of the ingestion of certain proton pump inhibitors. The cases against Pfizer involve Protonix and/or Nexium 24HR and seek compensatory and punitive damages and, in some cases, treble damages, restitution or disgorgement. In 2017, the federal actions were ordered transferred for coordinated pre-trial proceedings to a Multi-District Litigation in the U.S. District Court for the District of New Jersey. As part of our Consumer Healthcare JV transaction with GSK, the JV has agreed to assume, and to indemnify Pfizer for, liabilities arising out of such litigation to the extent related to Nexium 24HR. Docetaxel • Personal Injury Actions A number of lawsuits have been filed against Hospira and Pfizer in various federal and state courts alleging that plaintiffs who were treated with Docetaxel developed permanent hair loss. The significant majority of the cases also name other defendants, including the manufacturer of the branded product, Taxotere. Plaintiffs seek compensatory and punitive damages. In 2016, the federal cases were transferred for coordinated pre-trial proceedings to a Multi-District Litigation in the U.S. District Court for the Eastern District of Louisiana. • Mississippi Attorney General Government Action In 2018, the Attorney General of Mississippi filed a complaint in Mississippi state court against the manufacturer of the branded product and eight other manufacturers including Pfizer and Hospira, alleging, with respect to Pfizer and Hospira, a failure to warn about a risk of permanent hair loss in violation of the Mississippi Consumer Protection Act. The action seeks civil penalties and injunctive relief. Zantac A number of lawsuits have been filed against Pfizer in various federal and state courts alleging that plaintiffs developed various types of cancer, or face an increased risk of developing cancer, purportedly as a result of the ingestion of Zantac. The significant majority of these cases also name other defendants that have historically manufactured and/or sold Zantac. Pfizer has not sold Zantac since 2006, and only sold an OTC version of the product. Plaintiffs seek compensatory and punitive damages. In February 2020, the federal actions were transferred for coordinated pre-trial proceedings to a Multi-District Litigation in the U.S. District Court for the Southern District of Florida. Plaintiffs in the Multi-District Litigation have filed against Pfizer and many other defendants a master personal injury complaint, a consolidated consumer class action complaint alleging, among other things, claims under consumer protection statutes of all 50 states, and a medical monitoring complaint seeking to certify medical monitoring classes under the laws of 13 states. In addition, (i) Pfizer has received service of Canadian class action complaints naming Pfizer and other defendants, and seeking compensatory and punitive damages for personal injury and economic loss, allegedly arising from the defendants’ sale of Zantac in Canada; and (ii) the State of New Mexico and the Mayor and City Council of Baltimore separately filed civil actions against Pfizer and many other defendants in state court, alleging various state statutory and common law claims in connection with the defendants’ alleged sale of Zantac in those jurisdictions. In April 2021, a Judicial Council Coordinated Proceeding was created in the Superior Court of California in Alameda County to coordinate personal injury actions against Pfizer and other defendants filed in California state court. Chantix Beginning in August 2021, a number of putative class actions have been filed against Pfizer in various U.S. federal courts following Pfizer’s voluntary recall of Chantix due to the presence of a nitrosamine, N-nitroso-varenicline. Plaintiffs assert that they suffered economic harm purportedly as a result of purchasing Chantix or generic varenicline medicines sold by Pfizer. Plaintiffs seek to represent nationwide and state-specific classes and seek various remedies, including damages and medical monitoring. Similar putative class actions have been filed in Canada and Israel, where the product brand is Champix. A3. Legal Proceedings––Commercial and Other Matters Monsanto-Related Matters In 1997, Monsanto Company (Former Monsanto) contributed certain chemical manufacturing operations and facilities to a newly formed corporation, Solutia Inc. (Solutia), and spun off the shares of Solutia. In 2000, Former Monsanto merged with Pharmacia & Upjohn Company to form Pharmacia. Pharmacia then transferred its agricultural operations to a newly created subsidiary, named Monsanto Company (New Monsanto), which it spun off in a two-stage process that was completed in 2002. Pharmacia was acquired by Pfizer in 2003 and is a wholly owned subsidiary of Pfizer. In connection with its spin-off that was completed in 2002, New Monsanto assumed, and agreed to indemnify Pharmacia for, any liabilities related to Pharmacia’s former agricultural business. New Monsanto has defended and/or is defending Pharmacia in connection with various claims and litigation arising out of, or related to, the agricultural business, and has been indemnifying Pharmacia when liability has been imposed or settlement has been reached regarding such claims and litigation. In connection with its spin-off in 1997, Solutia assumed, and agreed to indemnify Pharmacia for, liabilities related to Former Monsanto’s chemical businesses. As the result of its reorganization under Chapter 11 of the U.S. Bankruptcy Code, Solutia’s indemnification obligations relating to Former Monsanto’s chemical businesses are primarily limited to sites that Solutia has owned or operated. In addition, in connection with its spin-off that was completed in 2002, New Monsanto assumed, and agreed to indemnify Pharmacia for, any liabilities primarily related to Former Monsanto’s chemical businesses, including, but not limited to, any such liabilities that Solutia assumed. Solutia’s and New Monsanto’s assumption of, and agreement to indemnify Pharmacia for, these liabilities apply to pending actions and any future actions related to Former Monsanto’s chemical businesses in which Pharmacia is named as a defendant, including, without limitation, actions asserting environmental claims, including alleged exposure to polychlorinated biphenyls. Solutia and/or New Monsanto are defending Pharmacia in connection with various claims and litigation arising out of, or related to, Former Monsanto’s chemical businesses, and have been indemnifying Pharmacia when liability has been imposed or settlement has been reached regarding such claims and litigation. Environmental Matters In 2009, we submitted a revised site-wide feasibility study with regard to the Wyeth Holdings Corporation (formerly, American Cyanamid Company) discontinued industrial chemical facility in Bound Brook, New Jersey. In 2011, Wyeth Holdings Corporation executed an Administrative Settlement Agreement and Order on Consent for Removal Action (the 2011 Administrative Settlement Agreement) with the U.S. Environmental Protection Agency (EPA) with regard to the Bound Brook facility. In accordance with the 2011 Administrative Settlement Agreement, we completed construction of an interim remedy. In 2012, the EPA issued a final remediation plan for the Bound Brook facility’s main plant area. In 2013, Wyeth Holdings Corporation (now Wyeth Holdings LLC) entered into an Administrative Settlement Agreement and Order on Consent with the EPA to allow us to undertake detailed engineering design of the remedy for the main plant area and to perform a focused feasibility study for two adjacent lagoons. In 2015, the U.S., on behalf of the EPA, filed a complaint and consent decree with the federal District Court for the District of New Jersey that allows Wyeth Holdings LLC to complete the design and to implement the remedy for the main plant area. The consent decree (which supersedes the 2011 Administrative Settlement Agreement) was entered by the District Court in 2015. In 2018, the EPA issued a final remediation plan for the two adjacent lagoons. In 2019, Wyeth Holdings LLC entered into an Administrative Settlement Agreement and Order on Consent with the EPA to allow us to undertake detailed engineering design of the remedy for the lagoons. In September 2021, the U.S., on behalf of the EPA, filed a complaint and consent decree with the federal District Court for the District of New Jersey, which the court approved in November 2021, that will allow Wyeth Holdings LLC to complete the design and implement the remedy for the two adjacent lagoons. We have accrued for the estimated costs of the site remedies for the Bound Brook faci

Segment, Geographic and Other R

Segment, Geographic and Other Revenue Information	3 Months Ended
	Apr. 03, 2022
Segment Reporting [Abstract]
Segment, Geographic and Other Revenue Information	Segment, Geographic and Other Revenue Information A. Segment Information We manage our commercial operations through two operating segments: Biopharma and PC1. The Biopharma and PC1 segments are each led by a single manager. Biopharma is the only reportable segment. Biopharma is a science-based medicines business that includes six therapeutic areas – Vaccines, Hospital, Oncology, Internal Medicine, Rare Disease, and Inflammation & Immunology. The Hospital therapeutic area commercializes our global portfolio of sterile injectable and anti-infective medicines, as well as an oral COVID-19 treatment. Each operating segment has responsibility for its commercial activities. Regional commercial organizations market, distribute and sell our products and are supported by global platform functions that are responsible for the research, development, manufacturing and supply of our products and global corporate enabling functions. Biopharma receives its R&D services from WRDM and GPD. These services include IPR&D projects for new investigational products and additional indications for in-line products. Each operating segment has a geographic footprint across developed and emerging markets. Our chief operating decision maker uses the revenues and earnings of the operating segments, among other factors, for performance evaluation and resource allocation. Other Costs and Business Activities–– Certain pre-tax costs are not allocated to our operating segment results, such as costs associated with: (i) R&D and medical expenses managed by our WRDM and GPD organizations, (ii) corporate enabling functions and other corporate costs, (iii) overhead costs primarily associated with our manufacturing operations, (iv) our share of earnings from the Consumer Healthcare JV, as well as (v) all amortization of intangible assets, acquisition-related items, and certain significant items representing substantive and/or unusual, and in some cases recurring, items that are evaluated on an individual basis by management and that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis. Beginning in the first quarter of 2022, acquisition-related items may now include the following purchase accounting impacts that previously would have been included as part of a reconciling item entitled “Purchase accounting adjustments” that we no longer separately present: (i) the incremental charge to cost of sales from the sale of acquired inventory that was written up to fair value, (ii) depreciation related to the increase/decrease in fair value of acquired fixed assets, (iii) amortization related to the increase in fair value of acquired debt and (iv) the fair value changes for contingent consideration. The operating results of PC1, our global contract development and manufacturing organization, are included in Other business activities. Segment Assets–– We manage our assets on a total company basis, not by operating segment, as our operating assets are shared or commingled. Therefore, our chief operating decision maker does not regularly review any asset information by operating segment and, accordingly, we do not report asset information by operating segment. Total assets were $184 billion as of April 3, 2022 and $181 billion as of December 31, 2021. Selected Income Statement Information The following provides selected income statement information by reportable segment: Three Months Ended Revenues Earnings (a) (MILLIONS) April 3, April 4, April 3, April 4, Reportable Segment: Biopharma $ 25,323 $ 14,125 $ 13,438 $ 8,383 Other business activities (b) 338 391 (2,475) (2,048) Reconciling Items: Amortization of intangible assets — — (835) (870) Acquisition-related items — — (187) 61 Certain significant items (c) — — (891) 166 $ 25,661 $ 14,516 $ 9,050 $ 5,692 (a) I ncome from continuing operations before provision/(benefit) for taxes on income. Biopharma’s earnings include dividend income from our investment in ViiV of $56 million in the first quarter of 2022 and $27 million in the first quarter of 2021. (b) Other business activities include revenues and costs associated with PC1, as well as costs that we do not allocate to our operating segments, per above. (c) Certain significant items are substantive and/or unusual, and in some cases recurring, items (as noted above). For earnings in the first quarter of 2022, includes, among other items, net losses on equity securities of $698 million recorded in Other (income)/deductions––net. For earnings in the first quarter of 2021, includes, among other items, net gains on equity securities of $399 million recorded in Other (income)/deductions––net . B. Geographic Information The following summarizes revenues by geographic area: Three Months Ended (MILLIONS) April 3, April 4, % United States $ 8,918 $ 7,530 18 Developed Europe 6,090 3,038 100 Developed Rest of World 3,286 1,123 193 Emerging Markets 7,367 2,824 161 Revenues $ 25,661 $ 14,516 77 C. Other Revenue Information Significant Customers–– For information on our significant wholesale customers, see Note 17C in our 2021 Form 10-K. Additionally, revenues from the U.S. government represented 19% of total revenues for the three months ended April 3, 2022, and primarily represent sales of Comirnaty and Paxlovid. Accounts receivable from the U.S. government represented 11% of total trade accounts receivable as of April 3, 2022, and primarily relate to sales of Comirnaty and Paxlovid. Significant Product Revenues The following provides detailed revenue information for several of our major products: (MILLIONS) Three Months Ended PRODUCT PRIMARY INDICATION OR CLASS April 3, April. 4, TOTAL REVENUES (a) $ 25,661 $ 14,516 PFIZER BIOPHARMACEUTICALS GROUP (BIOPHARMA) (a), (b) $ 25,323 $ 14,125 Vaccines $ 14,941 $ 4,894 Comirnaty direct sales and alliance revenues Active immunization to prevent COVID-19 13,227 3,462 Prevnar family (c) Pneumococcal disease 1,565 1,284 Nimenrix Meningococcal ACWY disease 77 46 FSME-IMMUN/TicoVac Tick-borne encephalitis disease 42 53 All other Vaccines Various 29 49 Hospital (a) $ 3,191 $ 1,886 Paxlovid COVID-19 infection (high risk population) 1,470 — Sulperazon Bacterial infections 210 192 Zithromax Bacterial infections 125 89 Ig Portfolio (d) Various 107 105 Zavicefta Bacterial infections 104 94 Medrol Anti-inflammatory glucocorticoid 76 99 Fragmin Treatment/prevention of venous thromboembolism 70 71 Vfend Fungal infections 65 80 All other Anti-infectives Various 381 455 All other Hospital Various 583 700 Oncology $ 2,967 $ 2,862 Ibrance HR-positive/HER2-negative metastatic breast cancer 1,237 1,254 Xtandi alliance revenues mCRPC, nmCRPC, mCSPC 268 267 Inlyta Advanced RCC 234 229 Zirabev (e) Treatment of mCRC; unresectable, locally advanced, recurrent or metastatic NSCLC; recurrent glioblastoma; metastatic RCC; and persistent, recurrent or metastatic cervical cancer 147 86 Bosulif Philadelphia chromosome–positive chronic myelogenous leukemia 128 123 Xalkori ALK-positive and ROS1-positive advanced NSCLC 127 134 Ruxience (e) Non-hodgkin’s lymphoma, chronic lymphocytic leukemia, granulomatosis with polyangiitis (Wegener’s Granulomatosis) and microscopic polyangiitis 124 98 Retacrit (e) Anemia 115 109 Sutent Advanced and/or metastatic RCC, adjuvant RCC, refractory GIST (after disease progression on, or intolerance to, imatinib mesylate) and advanced pancreatic neuroendocrine tumor 114 200 Lorbrena ALK-positive metastatic NSCLC 72 60 Bavencio alliance revenues Locally advanced or metastatic urothelial carcinoma; metastatic Merkel cell carcinoma; immunotherapy and tyrosine kinase inhibitor combination for patients with advanced RCC 67 32 Aromasin Post-menopausal early and advanced breast cancer 62 52 Trazimera (e) HER-positive breast cancer and metastatic stomach cancers 52 45 Besponsa Relapsed or refractory B-cell acute lymphoblastic leukemia 51 50 Braftovi In combination with Mektovi for metastatic melanoma in patients with a BRAF V600E/K mutation and, in combination with Erbitux ® (cetuximab), for the treatment of BRAF V600E -mutant mCRC after prior therapy 48 47 Mektovi In combination with Braftovi for metastatic melanoma in patients with a BRAF V600E/K mutation 40 35 All other Oncology Various 81 41 Internal Medicine $ 2,440 $ 2,594 Eliquis alliance revenues and direct sales Nonvalvular atrial fibrillation, deep vein thrombosis, pulmonary embolism 1,793 1,643 Premarin family Symptoms of menopause 102 143 BMP2 Development of bone and cartilage 67 49 Toviaz Overactive bladder 54 57 Chantix/Champix An aid to smoking cessation treatment in adults 18 years of age or older 2 217 All other Internal Medicine Various 423 484 Rare Disease $ 963 $ 824 Vyndaqel/Vyndamax ATTR-cardiomyopathy and polyneuropathy 612 453 BeneFIX Hemophilia B 112 112 (MILLIONS) Three Months Ended PRODUCT PRIMARY INDICATION OR CLASS April 3, April. 4, Genotropin Replacement of human growth hormone 80 80 Somavert Acromegaly 68 65 Refacto AF/Xyntha Hemophilia A 66 89 All other Rare Disease Various 25 26 Inflammation & Immunology (I&I) $ 821 $ 1,065 Xeljanz RA, PsA, UC, active polyarticular course juvenile idiopathic arthritis, ankylosing spondylitis 372 538 Enbrel (Outside the U.S. and Canada) RA, juvenile idiopathic arthritis, PsA, plaque psoriasis, pediatric plaque psoriasis, ankylosing spondylitis and nonradiographic axial spondyloarthritis 280 319 Inflectra (e) Crohn’s disease, pediatric Crohn’s disease, UC, pediatric UC, RA in combination with methotrexate, ankylosing spondylitis, PsA and plaque psoriasis 135 177 All other I&I Various 35 31 PFIZER CENTREONE (b) $ 338 $ 391 Total Alliance revenues $ 2,314 $ 1,770 Total Biosimilars (e) $ 605 $ 530 Total Sterile Injectable Pharmaceuticals (f) $ 1,331 $ 1,482 (a) On December 31, 2021, we completed the sale of our Meridian subsidiary. Prior to its sale, Meridian was managed as part of the Hospital therapeutic area. Beginning in the fourth quarter of 2021, the financial results of Meridian were reflected as discontinued operations. Prior-period financial information has been restated, as appropriate. See Note 1A . (b) At the beginning of our fiscal fourth quarter of 2021, we reorganized our commercial operations and began to manage our commercial operations through a new global structure consisting of two operating segments, each led by a single manager: Biopharma, our innovative science-based biopharmaceutical business, and PC1. PC1, which previously had been managed within the Hospital therapeutic area, includes revenues from our contract manufacturing, including certain Comirnaty-related manufacturing activities performed on behalf of BioNTech ($47 million for the first quarter of 2022), and revenues from our active pharmaceutical ingredient sales operation, as well as revenues related to our manufacturing and supply agreements with former legacy Pfizer businesses/partnerships, including but not limited to, transitional manufacturing and supply agreements with Viatris following the spin-off of the Upjohn Business. We have revised prior period information to conform to the current management structure. (c) Prevnar family include revenues from Prevnar 13/Prevenar 13 (pediatric and adult) and Prevnar 20 (adult). (d) Immunoglobulin (Ig) portfolio includes the revenues from Panzyga, Octagam and Cutaquig. (e) Biosimilars are highly similar versions of approved and authorized biological medicines and primarily include revenues from Zirabev, Inflectra, Ruxience, Retacrit, and Trazimera. (f) Total Sterile Injectable Pharmaceuticals represents the total of all branded and generic injectable products in the Hospital therapeutic area, including anti-infective sterile injectable pharmaceuticals. Remaining Performance Obligations–– Contracted revenue expected to be recognized from remaining performance obligations for firm orders in long-term contracts to supply Comirnaty to our customers totaled approximately $30 billion as of April 3, 2022, which includes amounts received in advance and deferred, as well as amounts that will be invoiced as we deliver these products to our customers in future periods. Of this amount, we expect to recognize revenue of approximately $18 billion in 2022, $12 billion in 2023 and $300 million in 2024. Remaining performance obligations exclude arrangements with an original expected contract duration of less than one year. Deferred Revenues–– Our deferred revenues primarily relate to advance payments received or receivable in connection with contracts that we entered into during 2022 and 2021 with various government or government sponsored customers in international markets for supply of Comirnaty and Paxlovid. The deferred revenues associated with the advance payments related to Comirnaty and Paxlovid total $3.3 billion as of April 3, 2022 and the deferred revenues associated with the advance payments of Comirnaty total $3.3 billion as of December 31, 2021, with $3.0 billion and $258 million recorded in current liabilities and noncurrent liabilities, respectively, as of April 3, 2022, and $3.0 billion and $249 million recorded in current liabilities and noncurrent liabilities, respectively, as of December 31, 2021. There were no deferred revenues associated with Paxlovid as of December 31, 2021. The Comirnaty and Paxlovid deferred revenue balances were effectively unchanged during the first three months of 2022 as amounts recognized in Revenues as we delivered the products to our customers were offset by additional advance payments received as we entered into new or amended contracts, including new advance payments received for Paxlovid contracts, and additional advance payments received as we invoiced customers in advance of product deliveries. During the first quarter of 2022, we recognized revenue of $1.6 billion that was included in the balance of Comirnaty deferred revenues as of December 31, 2021. The Comirnaty and Paxlovid deferred revenues as of April 3, 2022 will be recognized in Revenues proportionately as we transfer control of the products to our customers and satisfy our performance obligation under the contracts, with the amounts included in current liabilities expected to be recognized in Revenues within the next 12 months, and the amounts included in noncurrent liabilities expected to be recognized in Revenues in 2023 and in the first quarter of 2024. Deferred revenues associated with contracts for other products were not significant as of April 3, 2022 or December 31, 2021.

Basis of Presentation and Sig_2

Basis of Presentation and Significant Accounting Policies (Policies)	3 Months Ended
	Apr. 03, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	Basis of Presentation We prepared these condensed consolidated financial statements in conformity with U.S. GAAP, consistent in all material respects with those applied in our 2021 Form 10-K. As permitted under the SEC requirements for interim reporting, certain footnotes or other financial information have been condensed or omitted. These financial statements include all normal and recurring adjustments that are considered necessary for the fair statement of results for the interim periods presented. The information included in this Form 10-Q should be read in conjunction with the consolidated financial statements and accompanying notes included in our 2021 Form 10-K . Revenues, expenses, assets and liabilities can vary during each quarter of the year. Therefore, the results and trends in these interim financial statements may not be representative of those for the full year. Pfizer’s fiscal quarter-end for subsidiaries operating outside the U.S. is as of and for the three months ended February 27, 2022 and February 28, 2021, and for U.S. subsidiaries is as of and for the three months ended April 3, 2022 and April 4, 2021. At the beginning of our fiscal fourth quarter of 2021, we reorganized our commercial operations and began to manage our commercial operations through a new global structure consisting of two operating segments, each led by a single manager: Biopharma, our innovative science-based biopharmaceutical business, and PC1, our global contract development and manufacturing organization and a leading supplier of specialty active pharmaceutical ingredients. Biopharma is the only reportable segment. See Note 17A in our 2021 Form 10-K and Note 13 below . Business development activities completed in 2022 and 2021 impacted financial results in the periods presented. Discontinued operations in the periods presented relate to the previously divested Meridian subsidiary, Mylan-Japan collaboration and Upjohn Business. See Notes 1A and 2B in our 2021 Form 10-K, and Note 2B below. We have made certain reclassification adjustments to conform prior-period amounts to the current presentation for discontinued operations and segment reporting.
New Accounting Standard Adopted	New Accounting Standard Adopted in 2022On January 1, 2022, we early adopted a new accounting standard for contract assets and contract liabilities acquired in a business combination. Under the new standard, acquired contract assets and contract liabilities are required to be recognized and measured by the acquirer on the acquisition date in accordance with ASC 606. This new guidance generally results in the acquirer recognizing contract assets and contract liabilities at the same amounts that were recorded by the acquiree. Previously, these amounts were recognized by the acquirer at fair value as of the acquisition date. We adopted this new standard on a prospective basis and there was no impact to our consolidated financial statements.
Revenues and Trade Accounts Receivable	Revenues and Trade Accounts Receivable Revenue Recognition–– We record revenues from product sales when there is a transfer of control of the product from us to the customer. We typically determine transfer of control based on when the product is shipped or delivered and title passes to the customer. For certain contracts, the finished product may temporarily be stored at our location under a bill-and-hold arrangement. Revenue is recognized on bill-and-hold arrangements at the point in time when the customer obtains control of the product and all of the following criteria have been met: the arrangement is substantive; the product is identified separately as belonging to the customer; the product is ready for physical transfer to the customer; and we do not have the ability to use the product or direct it to another customer. In determining when the customer obtains control of the product, we consider certain indicators, including whether we have a present right to payment from the customer, whether title and/or significant risks and rewards of ownership have transferred to the customer and whether customer acceptance has been received. Customers–– Our prescription pharmaceutical products, with the exception of Paxlovid, are sold principally to wholesalers, but we also sell directly to retailers, hospitals, clinics, government agencies and pharmacies. We principally sell Paxlovid to government agencies. In the U.S., we primarily sell our vaccine products directly to the federal government, CDC, wholesalers, individual provider offices, retail pharmacies and integrated delivery networks. Outside the U.S., we primarily sell our vaccines to government and non-government institutions. Deductions from Revenues–– Our accruals for Medicare, Medicaid and related state program and performance-based contract rebates, chargebacks, sales allowances and sales returns and cash discounts are as follows: (MILLIONS) April 3, December 31, 2021 Reserve against Trade accounts receivable, less allowance for doubtful accounts $ 933 $ 1,077 Other current liabilities : Accrued rebates 3,858 3,811 Other accruals 440 528 Other noncurrent liabilities 299 433 Total accrued rebates and other sales-related accruals $ 5,530 $ 5,850 Trade Accounts Receivable–– Trade accounts receivable are stated at their net realizable value. The allowance for credit losses reflects our best estimate of expected credit losses of the receivables portfolio determined on the basis of historical experience, current information, and forecasts of future economic conditions. In developing the estimate for expected credit losses, trade accounts receivables are segmented into pools of assets depending on market (U.S. versus international), delinquency status, and customer type (high risk versus low risk and government versus non-government), and fixed reserve percentages are established for each pool of trade accounts receivables. In determining the reserve percentages for each pool of trade accounts receivables, we considered our historical experience with certain customers and customer types, regulatory and legal environments, country and political risk, and other relevant current and future forecasted macroeconomic factors. These credit risk indicators are monitored on a quarterly basis to determine whether there have been any changes in the economic environment that would indicate the established reserve percentages should be adjusted, and are considered on a regional basis to reflect more geographic-specific metrics. Additionally, write-offs and recoveries of customer receivables are tracked against collections on a quarterly basis to determine whether the reserve percentages remain appropriate. When management becomes aware of certain customer-specific factors that impact credit risk, specific allowances for these known troubled accounts are recorded. Trade accounts receivable are written off after all reasonable means to collect the full amount (including litigation, where appropriate) have been exhausted.
Acquired In-Process Research and Development Expenses	Acquired In-Process Research and Development Expenses In the first quarter of 2022, we began reporting acquired IPR&D expense as a separate line item in our consolidated statements of income. Acquired in-process research and development expenses includes costs incurred in connection with (a) all upfront and milestone payments on collaboration and in-license agreements, including premiums on equity securities and (b) asset acquisitions of acquired IPR&D. These costs were previously recorded in Research and development expenses . Prior periods have been revised to conform to the current period presentation. When we acquire net assets that do not constitute a business, as defined in U.S. GAAP, no goodwill is recognized and acquired IPR&D is expensed. The fair value of IPR&D acquired in connection with a business combination is recorded on the balance sheet as Identifiable intangible assets

Basis of Presentation and Sig_3

Basis of Presentation and Significant Accounting Policies (Tables)	3 Months Ended
	Apr. 03, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Balance Sheet Classification of Accruals	Our accruals for Medicare, Medicaid and related state program and performance-based contract rebates, chargebacks, sales allowances and sales returns and cash discounts are as follows: (MILLIONS) April 3, December 31, 2021 Reserve against Trade accounts receivable, less allowance for doubtful accounts $ 933 $ 1,077 Other current liabilities : Accrued rebates 3,858 3,811 Other accruals 440 528 Other noncurrent liabilities 299 433 Total accrued rebates and other sales-related accruals $ 5,530 $ 5,850

Acquisition, Discontinued Ope_2

Acquisition, Discontinued Operations, Equity-Method Investment and Collaborative Arrangement (Tables)	3 Months Ended
	Apr. 03, 2022
Business Combinations, Disposal Groups, Including Discontinued Operations, Equity Method Investments And Research And Development Arrangement [Abstract]
Equity Method Investment	Summarized financial information for our equity method investee, the Consumer Healthcare JV, for the three months ending December 31, 2021, the most recent period available, and for the three months ending December 31, 2020, is as follows: Three Months Ended (MILLIONS) December 31, 2021 December 31, 2020 Net sales $ 3,420 $ 3,096 Cost of sales (1,312) (1,188) Gross profit $ 2,108 $ 1,908 Income from continuing operations 590 233 Net income 590 233 Income attributable to shareholders 578 221

Restructuring Charges and Oth_2

Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives (Tables)	3 Months Ended
	Apr. 03, 2022
Restructuring and Related Activities [Abstract]
Schedule of Acquisitions and Cost-Reduction/Productivity Initiatives	The following summarizes acquisitions and cost-reduction/productivity initiatives costs and credits: Three Months Ended (MILLIONS) April 3, April 4, Restructuring charges/(credits): Employee terminations $ 25 $ 22 Asset impairments 8 (5) Exit costs/(credits) 11 — Restructuring charges/(credits) (a) 43 17 Transaction costs (b) 6 — Integration costs and other (c) 142 5 Restructuring charges and certain acquisition-related costs 192 22 Net periodic benefit costs/(credits) recorded in Other (income)/deductions––net (6) 8 Additional depreciation––asset restructuring recorded in our condensed consolidated statements of income, mainly in Cost of sales (d) 9 6 Implementation costs recorded in our condensed consolidated statements of income as follows (e) : Cost of sales 12 11 Selling, informational and administrative expenses 74 64 Total implementation costs 85 75 Total costs associated with acquisitions and cost-reduction/productivity initiatives $ 280 $ 111 (a) Primarily represents cost reduction initiatives. (b) Represents external costs for banking, legal, accounting and other similar services. (c) Represents external, incremental costs directly related to integrating acquired businesses, such as expenditures for consulting and the integration of systems and processes, and certain other qualifying costs. In the first quarter of 2022, integration costs and other were mostly related to our acquisition of Arena, including $138 million in payments to Arena employees for the fair value of previously unvested long-term incentive awards. See Note 2A. (d) Represents the impact of changes in the estimated useful lives of assets involved in restructuring actions. (e) Represents external, incremental costs directly related to implementing our non-acquisition-related cost-reduction/productivity initiatives.
Schedule of Components and Changes in Restructuring Accruals	The following summarizes the components and changes in restructuring accruals: (MILLIONS) Employee Asset Exit Costs Accrual Balance, December 31, 2021 (a) $ 1,014 $ — $ 57 $ 1,071 Provision 25 8 11 43 Utilization and other (b) (95) (8) (59) (163) Balance, April 3, 2022 (c) $ 943 $ — $ 9 $ 952 (a) Included in Other current liabilities ($816 million) and Other noncurrent liabilities ($255 million). (b) Includes adjustments for foreign currency translation. (c) Included in Other current liabilities ($812 million) and Other noncurrent liabilities ($140 million).

Other (Income)_Deductions - N_2

Other (Income)/Deductions - Net (Tables)	3 Months Ended
	Apr. 03, 2022
Other Income and Expenses [Abstract]
Schedule of Other (Income)/Deductions - Net	Components of Other (income)/deductions––net include: Three Months Ended (MILLIONS) April 3, April 4, Interest income $ (14) $ — Interest expense 322 336 Net interest expense 308 336 Royalty-related income (173) (176) Net (gains)/losses on asset disposals (1) (39) Net (gains)/losses recognized during the period on equity securities (a) 699 (401) Income from collaborations, out-licensing arrangements and sales of compound/product rights (b) (9) (231) Net periodic benefit costs/(credits) other than service costs (283) (266) Certain legal matters, net 79 51 Consumer Healthcare JV equity method (income)/loss (c) (184) (62) Other, net (88) (216) Other (income)/deductions––net $ 350 $ (1,004) (a) The losses in the first quarter of 2022 include, among other things, unrealized losses of $473 million related to our investment in BioNTech. The gains in the first quarter of 2021 included, among other things, unrealized gains of $409 million related to investments in Allogene Therapeutics, Inc. and BioNTech. (b) The first quarter of 2021 included, among other things, $188 million of net collaboration income from BioNTech related to Comirnaty. (c) See Note 2C .

Tax Matters (Tables)

Tax Matters (Tables)	3 Months Ended
	Apr. 03, 2022
Income Tax Disclosure [Abstract]
Schedule of Tax Provision/(Benefit) on Other Comprehensive Income (Loss)	Components of Tax provision/(benefit) on other comprehensive income/(loss) include: Three Months Ended (MILLIONS) April 3, April 4, Foreign currency translation adjustments, net (a) $ (72) $ 21 Unrealized holding gains/(losses) on derivative financial instruments, net 32 59 Reclassification adjustments for (gains)/losses included in net income (22) 34 10 93 Unrealized holding gains/(losses) on available-for-sale securities, net (17) 10 Reclassification adjustments for (gains)/losses included in net income 29 (30) 12 (20) Reclassification adjustments related to amortization of prior service costs and other, net (9) (10) Reclassification adjustments related to curtailments of prior service costs and other, net (2) — Other — — (11) (10) Tax provision/(benefit) on other comprehensive income/(loss) $ (60) $ 84 (a) Taxes are not provided for foreign currency translation adjustments relating to investments in international subsidiaries that we intend to hold indefinitely.

Accumulated Other Comprehensi_2

Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests (Tables)	3 Months Ended
	Apr. 03, 2022
Equity [Abstract]
Schedule of Changes in Accumulated Other Comprehensive Loss	The following summarizes the changes, net of tax, in Accumulated other comprehensive loss : Net Unrealized Gains/(Losses) Benefit Plans (MILLIONS) Foreign Currency Translation Adjustments Derivative Financial Instruments Available-For-Sale Securities Prior Service (Costs)/Credits and Other Accumulated Other Comprehensive Income/(Loss) Balance, December 31, 2021 $ (6,172) $ 119 $ (220) $ 377 $ (5,897) Other comprehensive income/(loss) (a) (291) (20) 87 (36) (260) Balance, April 3, 2022 $ (6,463) $ 99 $ (133) $ 341 $ (6,157) (a) Amounts do not include foreign currency translation adjustments attributable to noncontrolling interests. Foreign currency translation adjustments include net losses related to our equity method investment in the Consumer Healthcare JV (see Note 2C ) and the impact of our net investment hedging program.

Financial Instruments (Tables)

Financial Instruments (Tables)	3 Months Ended
	Apr. 03, 2022
Fair Value Disclosures [Abstract]
Schedule of Financial Assets and Liabilities Measured At Fair Value On a Recurring Basis	Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis and Fair Value Hierarchy, using a Market Approach: April 3, 2022 December 31, 2021 (MILLIONS) Total Level 1 Level 2 Total Level 1 Level 2 Financial assets: Short-term investments Classified as equity securities with readily determinable fair values: Money market funds $ 2,759 $ — $ 2,759 $ 5,365 $ — $ 5,365 Classified as available-for-sale debt securities: Government and agency—non-U.S. 14,548 — 14,548 17,318 — 17,318 Government and agency—U.S. 1,830 — 1,830 4,050 — 4,050 Corporate and other 958 — 958 647 — 647 17,337 — 17,337 22,014 — 22,014 Total short-term investments 20,096 — 20,096 27,379 — 27,379 Other current assets Derivative assets: Interest rate contracts 5 — 5 4 — 4 Foreign exchange contracts 832 — 832 704 — 704 Total other current assets 837 — 837 709 — 709 Long-term investments Classified as equity securities with readily determinable fair values (a) 3,486 3,470 15 3,876 3,849 27 Classified as available-for-sale debt securities: Government and agency—non-U.S. 519 — 519 465 — 465 Government and agency—U.S. 1 — 1 6 — 6 Corporate and other 49 — 49 50 — 50 569 — 569 521 — 521 Total long-term investments 4,055 3,470 584 4,397 3,849 548 Other noncurrent assets Derivative assets: Interest rate contracts — — — 16 — 16 Foreign exchange contracts 267 — 267 242 — 242 Total derivative assets 267 — 267 259 — 259 Insurance contracts (b) 765 — 765 808 — 808 Total other noncurrent assets 1,032 — 1,032 1,067 — 1,067 Total assets $ 26,020 $ 3,470 $ 22,550 $ 33,552 $ 3,849 $ 29,703 Financial liabilities: Other current liabilities Derivative liabilities: Foreign exchange contracts $ 330 $ — $ 330 $ 476 $ — $ 476 Total other current liabilities 330 — 330 476 — 476 Other noncurrent liabilities Derivative liabilities: Interest rate contracts 140 — 140 — — — Foreign exchange contracts 460 — 460 405 — 405 Total other noncurrent liabilities 600 — 600 405 — 405 Total liabilities $ 930 $ — $ 930 $ 881 $ — $ 881 (a) Long-term equity securities of $155 million as of April 3, 2022 and $194 million as of December 31, 2021 were held in restricted trusts for U.S. non-qualified employee benefit plans. (b) Includes life insurance policies held in restricted trusts for U.S. non-qualified employee benefit plans. The underlying invested assets in these contracts are marketable securities, which are carried at fair value, with changes in fair value recognized in Other (income)/deductions—net (see Note 4 ).
Investments by Classification Type	The following summarizes our investments by classification type: (MILLIONS) April 3, 2022 December 31, 2021 Short-term investments Equity securities with readily determinable fair values (a) $ 2,759 $ 5,365 Available-for-sale debt securities 17,337 22,014 Held-to-maturity debt securities 1,331 1,746 Total Short-term investments $ 21,427 $ 29,125 Long-term investments Equity securities with readily determinable fair values $ 3,486 $ 3,876 Available-for-sale debt securities 569 521 Held-to-maturity debt securities 41 34 Private equity securities at cost (b) 647 623 Total Long-term investments $ 4,742 $ 5,054 Equity-method investments 15,995 16,472 Total long-term investments and equity-method investments $ 20,737 $ 21,526 Held-to-maturity cash equivalents $ 458 $ 268 (a) As of April 3, 2022 and December 31, 2021, includes money market funds primarily invested in U.S. Treasury and government debt. (b) Represent investments in the life sciences sector.
Schedule of Held-to-maturity Securities	At April 3, 2022, our investment portfolio consisted of debt securities issued across diverse governments, corporate and financial institutions, which are investment-grade. The contractual or estimated maturities, are as follows: April 3, 2022 December 31, 2021 Gross Unrealized Maturities (in Years) Gross Unrealized (MILLIONS) Amortized Cost Gains Losses Fair Value Within 1 Over 1 Over 5 Amortized Cost Gains Losses Fair Value Available-for-sale debt securities Government and agency –– non-U.S. $ 15,217 $ 8 $ (158) $ 15,067 $ 14,548 $ 519 $ — $ 18,032 $ 13 $ (263) $ 17,783 Government and agency––U.S. 1,832 — (1) 1,831 1,830 1 — 4,056 — (1) 4,055 Corporate and other 1,009 — (1) 1,008 958 49 — 698 — (1) 697 Held-to-maturity debt securities Time deposits and other 1,015 — — 1,015 979 25 11 947 — — 947 Government and agency –– non-U.S. 814 — — 814 809 4 1 1,102 — — 1,102 Total debt securities $ 19,887 $ 8 $ (160) $ 19,735 $ 19,125 $ 598 $ 12 $ 24,835 $ 14 $ (265) $ 24,584
Schedule of Available-for-sale Securities	At April 3, 2022, our investment portfolio consisted of debt securities issued across diverse governments, corporate and financial institutions, which are investment-grade. The contractual or estimated maturities, are as follows: April 3, 2022 December 31, 2021 Gross Unrealized Maturities (in Years) Gross Unrealized (MILLIONS) Amortized Cost Gains Losses Fair Value Within 1 Over 1 Over 5 Amortized Cost Gains Losses Fair Value Available-for-sale debt securities Government and agency –– non-U.S. $ 15,217 $ 8 $ (158) $ 15,067 $ 14,548 $ 519 $ — $ 18,032 $ 13 $ (263) $ 17,783 Government and agency––U.S. 1,832 — (1) 1,831 1,830 1 — 4,056 — (1) 4,055 Corporate and other 1,009 — (1) 1,008 958 49 — 698 — (1) 697 Held-to-maturity debt securities Time deposits and other 1,015 — — 1,015 979 25 11 947 — — 947 Government and agency –– non-U.S. 814 — — 814 809 4 1 1,102 — — 1,102 Total debt securities $ 19,887 $ 8 $ (160) $ 19,735 $ 19,125 $ 598 $ 12 $ 24,835 $ 14 $ (265) $ 24,584
Contractual Maturities of Available-for-sale and Held-to-maturity Debt Securities	At April 3, 2022, our investment portfolio consisted of debt securities issued across diverse governments, corporate and financial institutions, which are investment-grade. The contractual or estimated maturities, are as follows: April 3, 2022 December 31, 2021 Gross Unrealized Maturities (in Years) Gross Unrealized (MILLIONS) Amortized Cost Gains Losses Fair Value Within 1 Over 1 Over 5 Amortized Cost Gains Losses Fair Value Available-for-sale debt securities Government and agency –– non-U.S. $ 15,217 $ 8 $ (158) $ 15,067 $ 14,548 $ 519 $ — $ 18,032 $ 13 $ (263) $ 17,783 Government and agency––U.S. 1,832 — (1) 1,831 1,830 1 — 4,056 — (1) 4,055 Corporate and other 1,009 — (1) 1,008 958 49 — 698 — (1) 697 Held-to-maturity debt securities Time deposits and other 1,015 — — 1,015 979 25 11 947 — — 947 Government and agency –– non-U.S. 814 — — 814 809 4 1 1,102 — — 1,102 Total debt securities $ 19,887 $ 8 $ (160) $ 19,735 $ 19,125 $ 598 $ 12 $ 24,835 $ 14 $ (265) $ 24,584
Schedule of Gains and Losses on Investment Securities	The following presents the calculation of the portion of unrealized (gains)/losses that relates to equity securities, excluding equity-method investments, held at the reporting date: Three Months Ended (MILLIONS) April 3, April 4, Net (gains)/losses recognized during the period on equity securities (a) $ 699 $ (401) Less: Net (gains)/losses recognized during the period on equity securities sold during the period (11) (28) Net unrealized (gains)/losses during the reporting period on equity securities still held at the reporting date (b) $ 710 $ (372) (a) Reported in Other (income)/deductions –– net. See Note 4 . (b) Included in net unrealized (gains)/losses are observable price changes on equity securities without readily determinable fair values. As of April 3, 2022, there were cumulative impairments and downward adjustments of $110 million and upward adjustments of $167 million. Impairments, downward and upward adjustments were not significant in the first quarters of 2022 and 2021.
Schedule of Short-term Borrowings	Short-term borrowings include: (MILLIONS) April 3, December 31, 2021 Current portion of long-term debt, principal amount $ 251 $ 1,636 Other short-term borrowings, principal amount (a) 385 605 Total short-term borrowings, principal amount 636 2,241 Net fair value adjustments related to hedging and purchase accounting 9 — Total Short-term borrowings, including current portion of long-term debt , carried at historical proceeds, as adjusted $ 645 $ 2,241 (a) Primarily includes cash collateral. See Note 7F .
Schedule of Principal Amounts of Senior Unsecured Long-Term Debt and Adjustments	The following summarizes the aggregate principal amount of our senior unsecured long-term debt, and adjustments to report our aggregate long-term debt: (MILLIONS) April 3, December 31, 2021 Total long-term debt, principal amount $ 34,603 $ 34,948 Net fair value adjustments related to hedging and purchase accounting 1,240 1,438 Net unamortized discounts, premiums and debt issuance costs (190) (195) Other long-term debt 3 4 Total long-term debt, carried at historical proceeds, as adjusted $ 35,656 $ 36,195 Current portion of long-term debt, carried at historical proceeds, as adjusted (not included above) $ 260 $ 1,636
Schedule of Derivative Instruments	The following summarizes the fair value of the derivative financial instruments and notional amounts (including those reported as part of discontinued operations): April 3, 2022 December 31, 2021 Fair Value Fair Value (MILLIONS) Notional Asset Liability Notional Asset Liability Derivatives designated as hedging instruments : Foreign exchange contracts (a) $ 29,833 $ 899 $ 647 $ 29,576 $ 787 $ 717 Interest rate contracts 2,250 5 140 2,250 21 — 904 787 808 717 Derivatives not designated as hedging instruments : Foreign exchange contracts $ 22,009 200 143 $ 21,419 160 164 Total $ 1,104 $ 930 $ 968 $ 881 (a) The notional amount of outstanding foreign exchange contracts hedging our intercompany forecasted inventory sales was $4.7 billion as of April 3, 2022 and $4.8 billion as of December 31, 2021.
Schedule of Derivative Assets	The following summarizes the fair value of the derivative financial instruments and notional amounts (including those reported as part of discontinued operations): April 3, 2022 December 31, 2021 Fair Value Fair Value (MILLIONS) Notional Asset Liability Notional Asset Liability Derivatives designated as hedging instruments : Foreign exchange contracts (a) $ 29,833 $ 899 $ 647 $ 29,576 $ 787 $ 717 Interest rate contracts 2,250 5 140 2,250 21 — 904 787 808 717 Derivatives not designated as hedging instruments : Foreign exchange contracts $ 22,009 200 143 $ 21,419 160 164 Total $ 1,104 $ 930 $ 968 $ 881 (a) The notional amount of outstanding foreign exchange contracts hedging our intercompany forecasted inventory sales was $4.7 billion as of April 3, 2022 and $4.8 billion as of December 31, 2021.
Schedule of Derivative Liabilities	The following summarizes the fair value of the derivative financial instruments and notional amounts (including those reported as part of discontinued operations): April 3, 2022 December 31, 2021 Fair Value Fair Value (MILLIONS) Notional Asset Liability Notional Asset Liability Derivatives designated as hedging instruments : Foreign exchange contracts (a) $ 29,833 $ 899 $ 647 $ 29,576 $ 787 $ 717 Interest rate contracts 2,250 5 140 2,250 21 — 904 787 808 717 Derivatives not designated as hedging instruments : Foreign exchange contracts $ 22,009 200 143 $ 21,419 160 164 Total $ 1,104 $ 930 $ 968 $ 881 (a) The notional amount of outstanding foreign exchange contracts hedging our intercompany forecasted inventory sales was $4.7 billion as of April 3, 2022 and $4.8 billion as of December 31, 2021.
Information about Gains/(Losses) Incurred to Hedge or Offset Operational Foreign Exchange or Interest Rate Risk	The following summarizes information about the gains/(losses) incurred to hedge or offset operational foreign exchange or interest rate risk exposures (including those reported as part of discontinued operations): Gains/(Losses) (a) Gains/(Losses) (a) Gains/(Losses) Reclassified from OCI into OID and COS (a) Three Months Ended (MILLIONS) April 3, April. 4, April 3, April. 4, April 3, April. 4, Derivative Financial Instruments in Cash Flow Hedge Relationships: Foreign exchange contracts (b) $ — $ — $ 187 $ 202 $ 195 $ (268) Amount excluded from effectiveness testing and amortized into earnings (c) — — 16 12 18 9 Derivative Financial Instruments in Fair Value Hedge Relationships: Interest rate contracts (156) (26) — — — — Hedged item 156 26 — — — — Derivative Financial Instruments in Net Investment Hedge Relationships: Foreign exchange contracts — — 259 154 — — Amount excluded from effectiveness testing and amortized into earnings (c) — — (74) (1) 30 29 Non-Derivative Financial Instruments in Net Investment Hedge Relationships: (d) Foreign currency short-term borrowings — — 26 38 — — Foreign currency long-term debt — — 23 56 — — Derivative Financial Instruments Not Designated as Hedges: Foreign exchange contracts (19) 42 — — — — $ (19) $ 42 $ 436 $ 460 $ 243 $ (230) (a) OID = Other (income)/deductions—net, included in Other (income)/deductions—net in the condensed consolidated statements of income . COS = Cost of Sales, included in Cost of sales in the condensed consolidated statements of income. OCI = Other comprehensive income/(loss), included in the condensed consolidated statements of comprehensive income . (b) The amounts reclassified from OCI into COS were: • a net gain of $34 million in the first quarter of 2022; and • a net loss of $45 million in the first quarter of 2021. The remaining amounts were reclassified from OCI into OID. Based on quarter-end foreign exchange rates that are subject to change, we expect to reclassify a pre-tax gain of $332 million within the next 12 months into income . The maximum length of time over which we are hedging our exposure to the variability in future foreign exchange cash flows is approximately 21 years and relates to foreign currency debt. (c) The amounts reclassified from OCI were reclassified into OID. (d) Short-term borrowings and long-term debt include foreign currency borrowings which are used in net investment hedges. The short-term borrowings’ carrying value as of December 31, 2021 was $1.1 billion. The long-term debt carrying values as of April 3, 2022 and December 31, 2021 were $821 million and $844 million, respectively.
Schedule of Total Amount of Each Income and Expense Line in which Results of Fair Value Hedges are Recorded	The following summarizes cumulative basis adjustments to our debt in fair value hedges: April 3, 2022 December 31, 2021 Cumulative Amount of Fair Value Hedging Adjustment Increase/(Decrease) to Cumulative Amount of Fair Value Hedging Adjustment Increase/(Decrease) to (MILLIONS) Carrying Amount of Hedged Assets/Liabilities (a) Active Hedging Relationships Discontinued Hedging Relationships Carrying Amount of Hedged Assets/Liabilities (a) Active Hedging Relationships Discontinued Hedging Relationships Short-term borrowings, including current portion of long-term debt $ — $ — $ 4 $ — $ — $ — Long-term debt $ 2,234 $ (140) $ 1,124 $ 2,233 $ 16 $ 1,154 (a) Carrying amounts exclude the cumulative amount of fair value hedging adjustments.

Other Financial Information (Ta

Other Financial Information (Tables)	3 Months Ended
	Apr. 03, 2022
Other Financial Information [Abstract]
Schedule of Components of Inventories, Current	The following summarizes the components of Inventories : (MILLIONS) April 3, December 31, 2021 Finished goods $ 3,633 $ 3,641 Work-in-process 4,843 4,424 Raw materials and supplies 1,502 994 Inventories (a) $ 9,979 $ 9,059 Noncurrent inventories not included above (b) $ 894 $ 939 (a) The change from December 31, 2021 reflects increases for Paxlovid and Comirnaty, as well as increases for certain products mainly for network strategy and supply recovery, partially offset by decreases due to market demand. (b) Included in Other noncurrent assets . There are no recoverability issues for these amounts.
Schedule of Components of Inventories, Noncurrent	The following summarizes the components of Inventories : (MILLIONS) April 3, December 31, 2021 Finished goods $ 3,633 $ 3,641 Work-in-process 4,843 4,424 Raw materials and supplies 1,502 994 Inventories (a) $ 9,979 $ 9,059 Noncurrent inventories not included above (b) $ 894 $ 939 (a) The change from December 31, 2021 reflects increases for Paxlovid and Comirnaty, as well as increases for certain products mainly for network strategy and supply recovery, partially offset by decreases due to market demand. (b) Included in Other noncurrent assets . There are no recoverability issues for these amounts.

Identifiable Intangible Assets

Identifiable Intangible Assets (Tables)	3 Months Ended
	Apr. 03, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Finite-Lived Intangible Assets	The following summarizes the components of Identifiable intangible assets : April 3, 2022 December 31, 2021 (MILLIONS) Gross Accumulated Identifiable Gross Accumulated Identifiable Finite-lived intangible assets Developed technology rights $ 73,212 $ (54,397) $ 18,815 $ 73,346 $ (53,732) $ 19,614 Brands 922 (816) 106 922 (807) 115 Licensing agreements and other 2,302 (1,329) 973 2,284 (1,299) 985 76,436 (56,542) 19,894 76,552 (55,838) 20,714 Indefinite-lived intangible assets Brands 827 827 827 827 IPR&D (a) 8,122 8,122 3,092 3,092 Licensing agreements and other (a) 973 973 513 513 9,922 9,922 4,432 4,432 Identifiable intangible assets (a), (b) $ 86,358 $ (56,542) $ 29,816 $ 80,984 $ (55,838) $ 25,146 (a) The increase in the gross carrying amounts mainly reflect the impact of the acquisition of Arena. See Note 2A . (b) The increase is primarily due to the acquisition of Arena, partially offset by amortization expense.
Schedule of Indefinite Lived Intangible Assets	The following summarizes the components of Identifiable intangible assets : April 3, 2022 December 31, 2021 (MILLIONS) Gross Accumulated Identifiable Gross Accumulated Identifiable Finite-lived intangible assets Developed technology rights $ 73,212 $ (54,397) $ 18,815 $ 73,346 $ (53,732) $ 19,614 Brands 922 (816) 106 922 (807) 115 Licensing agreements and other 2,302 (1,329) 973 2,284 (1,299) 985 76,436 (56,542) 19,894 76,552 (55,838) 20,714 Indefinite-lived intangible assets Brands 827 827 827 827 IPR&D (a) 8,122 8,122 3,092 3,092 Licensing agreements and other (a) 973 973 513 513 9,922 9,922 4,432 4,432 Identifiable intangible assets (a), (b) $ 86,358 $ (56,542) $ 29,816 $ 80,984 $ (55,838) $ 25,146 (a) The increase in the gross carrying amounts mainly reflect the impact of the acquisition of Arena. See Note 2A . (b) The increase is primarily due to the acquisition of Arena, partially offset by amortization expense.
Schedule of Goodwill	The following summarizes the changes in the carrying amount of Goodwill : (MILLIONS) Total (a) Balance, January 1, 2022 $ 49,208 Additions (b) 1,023 Other (c) (21) Balance, April 3, 2022 $ 50,211 (a) All goodwill is assigned within the Biopharma reportable segment. (b) Additions relate to our acquisition of Arena. See Note 2A . (c) Other represents the impact of foreign exchange.

Pension and Postretirement Be_2

Pension and Postretirement Benefit Plans (Tables)	3 Months Ended
	Apr. 03, 2022
Retirement Benefits [Abstract]
Schedule of Net Periodic Benefit Costs	The following summarizes the components of net periodic benefit cost/(credit): Pension Plans U.S. International Postretirement Three Months Ended (MILLIONS) April 3, April. 4, April 3, April. 4, April 3, April. 4, Service cost $ — $ — $ 30 $ 33 $ 7 $ 9 Interest cost 118 113 42 36 7 7 Expected return on plan assets (245) (261) (79) (82) (12) (10) Amortization of prior service credits — (1) — — (36) (39) Actuarial (gains)/losses (a) (65) (47) — — — — Curtailments — — — — (13) — Special termination benefits 6 7 — — — 1 Net periodic benefit cost/(credit) reported in income $ (186) $ (187) $ (8) $ (12) $ (46) $ (32) (a) Mainly reflects interim actuarial remeasurement gains in 2022, primarily due to an increase in the discount rate.

Earnings Per Common Share Att_2

Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders (Tables)	3 Months Ended
	Apr. 03, 2022
Earnings Per Share [Abstract]
Schedule of Basic and Diluted Earning Per Share	The following presents the detailed calculation of EPS : Three Months Ended (MILLIONS) April 3, April 4, EPS Numerator––Basic Income from continuing operations attributable to Pfizer Inc. common shareholders $ 7,872 $ 4,876 Discontinued operations––net of tax (9) 1 Net income attributable to Pfizer Inc. common shareholders $ 7,864 $ 4,877 EPS Numerator––Diluted Income from continuing operations attributable to Pfizer Inc. common shareholders and assumed conversions $ 7,872 $ 4,876 Discontinued operations––net of tax, attributable to Pfizer Inc. common shareholders and assumed conversions (9) 1 Net income attributable to Pfizer Inc. common shareholders and assumed conversions $ 7,864 $ 4,877 EPS Denominator Weighted-average number of common shares outstanding––Basic 5,617 5,584 Common-share equivalents: stock options and stock issuable under employee compensation plans 141 78 Weighted-average number of common shares outstanding––Diluted 5,758 5,662 Anti-dilutive common stock equivalents (a) — 2 (a) These common stock equivalents were outstanding for the periods presented, but were not included in the computation of diluted EPS for those periods because their inclusion would have had an anti-dilutive effect.

Segment, Geographic and Other_2

Segment, Geographic and Other Revenue Information (Tables)	3 Months Ended
	Apr. 03, 2022
Segment Reporting [Abstract]
Schedule of Segment Reporting Information by Segment	The following provides selected income statement information by reportable segment: Three Months Ended Revenues Earnings (a) (MILLIONS) April 3, April 4, April 3, April 4, Reportable Segment: Biopharma $ 25,323 $ 14,125 $ 13,438 $ 8,383 Other business activities (b) 338 391 (2,475) (2,048) Reconciling Items: Amortization of intangible assets — — (835) (870) Acquisition-related items — — (187) 61 Certain significant items (c) — — (891) 166 $ 25,661 $ 14,516 $ 9,050 $ 5,692 (a) I ncome from continuing operations before provision/(benefit) for taxes on income. Biopharma’s earnings include dividend income from our investment in ViiV of $56 million in the first quarter of 2022 and $27 million in the first quarter of 2021. (b) Other business activities include revenues and costs associated with PC1, as well as costs that we do not allocate to our operating segments, per above. (c) Certain significant items are substantive and/or unusual, and in some cases recurring, items (as noted above). For earnings in the first quarter of 2022, includes, among other items, net losses on equity securities of $698 million recorded in Other (income)/deductions––net. For earnings in the first quarter of 2021, includes, among other items, net gains on equity securities of $399 million recorded in Other (income)/deductions––net .
Schedule of Revenues by Geographic Region	The following summarizes revenues by geographic area: Three Months Ended (MILLIONS) April 3, April 4, % United States $ 8,918 $ 7,530 18 Developed Europe 6,090 3,038 100 Developed Rest of World 3,286 1,123 193 Emerging Markets 7,367 2,824 161 Revenues $ 25,661 $ 14,516 77
Schedule of Significant Product Revenues	The following provides detailed revenue information for several of our major products: (MILLIONS) Three Months Ended PRODUCT PRIMARY INDICATION OR CLASS April 3, April. 4, TOTAL REVENUES (a) $ 25,661 $ 14,516 PFIZER BIOPHARMACEUTICALS GROUP (BIOPHARMA) (a), (b) $ 25,323 $ 14,125 Vaccines $ 14,941 $ 4,894 Comirnaty direct sales and alliance revenues Active immunization to prevent COVID-19 13,227 3,462 Prevnar family (c) Pneumococcal disease 1,565 1,284 Nimenrix Meningococcal ACWY disease 77 46 FSME-IMMUN/TicoVac Tick-borne encephalitis disease 42 53 All other Vaccines Various 29 49 Hospital (a) $ 3,191 $ 1,886 Paxlovid COVID-19 infection (high risk population) 1,470 — Sulperazon Bacterial infections 210 192 Zithromax Bacterial infections 125 89 Ig Portfolio (d) Various 107 105 Zavicefta Bacterial infections 104 94 Medrol Anti-inflammatory glucocorticoid 76 99 Fragmin Treatment/prevention of venous thromboembolism 70 71 Vfend Fungal infections 65 80 All other Anti-infectives Various 381 455 All other Hospital Various 583 700 Oncology $ 2,967 $ 2,862 Ibrance HR-positive/HER2-negative metastatic breast cancer 1,237 1,254 Xtandi alliance revenues mCRPC, nmCRPC, mCSPC 268 267 Inlyta Advanced RCC 234 229 Zirabev (e) Treatment of mCRC; unresectable, locally advanced, recurrent or metastatic NSCLC; recurrent glioblastoma; metastatic RCC; and persistent, recurrent or metastatic cervical cancer 147 86 Bosulif Philadelphia chromosome–positive chronic myelogenous leukemia 128 123 Xalkori ALK-positive and ROS1-positive advanced NSCLC 127 134 Ruxience (e) Non-hodgkin’s lymphoma, chronic lymphocytic leukemia, granulomatosis with polyangiitis (Wegener’s Granulomatosis) and microscopic polyangiitis 124 98 Retacrit (e) Anemia 115 109 Sutent Advanced and/or metastatic RCC, adjuvant RCC, refractory GIST (after disease progression on, or intolerance to, imatinib mesylate) and advanced pancreatic neuroendocrine tumor 114 200 Lorbrena ALK-positive metastatic NSCLC 72 60 Bavencio alliance revenues Locally advanced or metastatic urothelial carcinoma; metastatic Merkel cell carcinoma; immunotherapy and tyrosine kinase inhibitor combination for patients with advanced RCC 67 32 Aromasin Post-menopausal early and advanced breast cancer 62 52 Trazimera (e) HER-positive breast cancer and metastatic stomach cancers 52 45 Besponsa Relapsed or refractory B-cell acute lymphoblastic leukemia 51 50 Braftovi In combination with Mektovi for metastatic melanoma in patients with a BRAF V600E/K mutation and, in combination with Erbitux ® (cetuximab), for the treatment of BRAF V600E -mutant mCRC after prior therapy 48 47 Mektovi In combination with Braftovi for metastatic melanoma in patients with a BRAF V600E/K mutation 40 35 All other Oncology Various 81 41 Internal Medicine $ 2,440 $ 2,594 Eliquis alliance revenues and direct sales Nonvalvular atrial fibrillation, deep vein thrombosis, pulmonary embolism 1,793 1,643 Premarin family Symptoms of menopause 102 143 BMP2 Development of bone and cartilage 67 49 Toviaz Overactive bladder 54 57 Chantix/Champix An aid to smoking cessation treatment in adults 18 years of age or older 2 217 All other Internal Medicine Various 423 484 Rare Disease $ 963 $ 824 Vyndaqel/Vyndamax ATTR-cardiomyopathy and polyneuropathy 612 453 BeneFIX Hemophilia B 112 112 (MILLIONS) Three Months Ended PRODUCT PRIMARY INDICATION OR CLASS April 3, April. 4, Genotropin Replacement of human growth hormone 80 80 Somavert Acromegaly 68 65 Refacto AF/Xyntha Hemophilia A 66 89 All other Rare Disease Various 25 26 Inflammation & Immunology (I&I) $ 821 $ 1,065 Xeljanz RA, PsA, UC, active polyarticular course juvenile idiopathic arthritis, ankylosing spondylitis 372 538 Enbrel (Outside the U.S. and Canada) RA, juvenile idiopathic arthritis, PsA, plaque psoriasis, pediatric plaque psoriasis, ankylosing spondylitis and nonradiographic axial spondyloarthritis 280 319 Inflectra (e) Crohn’s disease, pediatric Crohn’s disease, UC, pediatric UC, RA in combination with methotrexate, ankylosing spondylitis, PsA and plaque psoriasis 135 177 All other I&I Various 35 31 PFIZER CENTREONE (b) $ 338 $ 391 Total Alliance revenues $ 2,314 $ 1,770 Total Biosimilars (e) $ 605 $ 530 Total Sterile Injectable Pharmaceuticals (f) $ 1,331 $ 1,482 (a) On December 31, 2021, we completed the sale of our Meridian subsidiary. Prior to its sale, Meridian was managed as part of the Hospital therapeutic area. Beginning in the fourth quarter of 2021, the financial results of Meridian were reflected as discontinued operations. Prior-period financial information has been restated, as appropriate. See Note 1A . (b) At the beginning of our fiscal fourth quarter of 2021, we reorganized our commercial operations and began to manage our commercial operations through a new global structure consisting of two operating segments, each led by a single manager: Biopharma, our innovative science-based biopharmaceutical business, and PC1. PC1, which previously had been managed within the Hospital therapeutic area, includes revenues from our contract manufacturing, including certain Comirnaty-related manufacturing activities performed on behalf of BioNTech ($47 million for the first quarter of 2022), and revenues from our active pharmaceutical ingredient sales operation, as well as revenues related to our manufacturing and supply agreements with former legacy Pfizer businesses/partnerships, including but not limited to, transitional manufacturing and supply agreements with Viatris following the spin-off of the Upjohn Business. We have revised prior period information to conform to the current management structure. (c) Prevnar family include revenues from Prevnar 13/Prevenar 13 (pediatric and adult) and Prevnar 20 (adult). (d) Immunoglobulin (Ig) portfolio includes the revenues from Panzyga, Octagam and Cutaquig. (e) Biosimilars are highly similar versions of approved and authorized biological medicines and primarily include revenues from Zirabev, Inflectra, Ruxience, Retacrit, and Trazimera. (f) Total Sterile Injectable Pharmaceuticals represents the total of all branded and generic injectable products in the Hospital therapeutic area, including anti-infective sterile injectable pharmaceuticals.

Basis of Presentation and Sig_4

Basis of Presentation and Significant Accounting Policies - Narrative (Details)	3 Months Ended
	Apr. 03, 2022operatingSegment
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Number of segments	2

Basis of Presentation and Sig_5

Basis of Presentation and Significant Accounting Policies - Schedule of Balance Sheet Classification of Accruals (Details) - USD ($) $ in Millions	Apr. 03, 2022	Dec. 31, 2021
Schedule Of Accrued Liabilities [Line Items]
Total accrued rebates and other sales-related accruals	$ 5,530	$ 5,850
Trade accounts receivable, less allowance for doubtful accounts [Member]
Schedule Of Accrued Liabilities [Line Items]
Total accrued rebates and other sales-related accruals	933	1,077
Other current liabilities [Member]
Schedule Of Accrued Liabilities [Line Items]
Accrued rebates	3,858	3,811
Other accruals	440	528
Other noncurrent liabilities [Member]
Schedule Of Accrued Liabilities [Line Items]
Total accrued rebates and other sales-related accruals	$ 299	$ 433

Acquisition, Discontinued Ope_3

Acquisition, Discontinued Operations, Equity-Method Investment and Collaborative Arrangement - Acquisitions Narrative (Details) - USD ($) $ / shares in Units, $ in Millions		Mar. 11, 2022	Apr. 03, 2022	Apr. 04, 2021	Dec. 31, 2021
Business Acquisition [Line Items]
Payments to acquire businesses, net of cash acquired			$ 6,225	$ 0
Goodwill	[1]		50,211		$ 49,208
Arena [Member]
Business Acquisition [Line Items]
Business acquisition, per share in cash (in dollars per share)		$ 100
Payments to acquire businesses, gross		$ 6,600
Payments to acquire businesses, net of cash acquired		6,200
Intangible assets acquired		5,500
Goodwill		1,000
Net deferred tax liabilities		510
Arena [Member] | Restructuring Charges And Acquisition-Related Costs [Member]
Business Acquisition [Line Items]
Post closing compensation expense		138	$ 138
IPR&D [Member] | Arena [Member]
Business Acquisition [Line Items]
Intangible assets acquired		5,000
Licensing Agreements [Member] | Arena [Member]
Business Acquisition [Line Items]
Intangible assets acquired		$ 460
[1]	All goodwill is assigned within the Biopharma reportable segment.

Acquisition, Discontinued Ope_4

Acquisition, Discontinued Operations, Equity-Method Investment and Collaborative Arrangement - Discontinued Operations Narrative (Details) - Viatris [Member] - USD ($) $ in Millions	3 Months Ended
	Apr. 04, 2021	Apr. 03, 2022	Dec. 31, 2021
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Nontrade receivables		$ 133	$ 53
Payment pursuant to terms of the separation agreement	$ 277

Acquisition, Discontinued Ope_5

Acquisition, Discontinued Operations, Equity-Method Investment and Collaborative Arrangement - Equity Method Investment Narrative (Details) € in Millions, £ in Millions, $ in Millions	3 Months Ended
	Apr. 03, 2022USD ($)	Apr. 04, 2021USD ($)	Jul. 03, 2022GBP (£)	Mar. 31, 2022USD ($)	Mar. 31, 2022EUR (€)	Mar. 31, 2022GBP (£)	Dec. 31, 2021USD ($)	Jul. 31, 2019
Schedule of Equity Method Investments [Line Items]
Equity-method investments	$ 15,995						$ 16,472
Unsecured Debt [Member] | 1.365% Consumer Healthcare JV Loan [Member] | Forecast [Member]
Schedule of Equity Method Investments [Line Items]
Debt instrument, face amount | £			£ 2,900
Stated interest rate			1.365%
Consumer Healthcare JV [Member]
Schedule of Equity Method Investments [Line Items]
Equity method investment, ownership percentage				32.00%	32.00%	32.00%		32.00%
Equity-method investments	15,800						$ 16,300
Decrease due to foreign currency translation	508
Dividend received	177
Equity method investment earnings	$ 185	$ 71
Consumer Healthcare JV [Member] | Forecast [Member]
Schedule of Equity Method Investments [Line Items]
Equity method investment, ownership percentage			32.00%
GSK [Member] | Consumer Healthcare JV [Member] | Disposed of by Sale [Member]
Schedule of Equity Method Investments [Line Items]
Proposed percent of ownership disposal				80.00%	80.00%	80.00%
GSK [Member] | Consumer Healthcare JV [Member]
Schedule of Equity Method Investments [Line Items]
Equity method investment, ownership percentage								68.00%
Consumer Healthcare JV [Member] | Senior Notes [Member] | Senior Notes, USD Denominated [Member]
Schedule of Equity Method Investments [Line Items]
Debt instrument, face amount				$ 8,750
Consumer Healthcare JV [Member] | Senior Notes [Member] | Senior Notes, EUR Denominated [Member]
Schedule of Equity Method Investments [Line Items]
Debt instrument, face amount | €					€ 2,350
Consumer Healthcare JV [Member] | Senior Notes [Member] | Senior Notes, GBP Denominated [Member]
Schedule of Equity Method Investments [Line Items]
Debt instrument, face amount | £						£ 700

Acquisition, Discontinued Ope_6

Acquisition, Discontinued Operations, Equity-Method Investment and Collaborative Arrangement - Schedule of Equity-Method Investment (Details) - USD ($) $ in Millions	3 Months Ended
	Apr. 03, 2022	Dec. 31, 2021	Apr. 04, 2021	Dec. 31, 2020
Schedule of Equity Method Investments [Line Items]
Income from continuing operations	$ 7,879		$ 4,885
Net income	7,870		4,886
Income attributable to shareholders	$ 7,864		$ 4,877
Consumer Healthcare JV [Member]
Schedule of Equity Method Investments [Line Items]
Net sales		$ 3,420		$ 3,096
Cost of sales		(1,312)		(1,188)
Gross profit		2,108		1,908
Income from continuing operations		590		233
Net income		590		233
Income attributable to shareholders		$ 578		$ 221

Acquisition, Discontinued Ope_7

Acquisition, Discontinued Operations, Equity-Method Investment and Collaborative Arrangement - Collaborative Arrangements (Detail) - Collaborative Arrangement [Member] - Biohaven [Member] $ in Millions	Jan. 04, 2022USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Payment to collaborators	$ 500
Upfront payment to collaborators	150
Committed investment from collaborator	350
Collaborative arrangement, milestone payment upon commercializing (up to)	740
Acquired In-Process Research and Development Expense [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Upfront payment and premium paid in equity investment	$ 263

Restructuring Charges and Oth_3

Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Narrative (Details) - Focused Company Plan [Member] - USD ($) $ in Millions	3 Months Ended	12 Months Ended
	Apr. 03, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Restructuring Cost and Reserve [Line Items]
Restructuring cost incurred to date	$ 2,300
Biopharma [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring cost incurred to date	875
Restructuring costs incurred	20	$ 712	$ 79	$ 64
Corporate Enabling Functions [Member]
Restructuring Cost and Reserve [Line Items]
Expected restructuring cost	1,800
Go-to Market Model [Member]
Restructuring Cost and Reserve [Line Items]
Expected restructuring cost	1,100
Manufacturing Optimization [Member]
Restructuring Cost and Reserve [Line Items]
Expected restructuring cost	$ 800
Percentage of expected costs to be non-cash	25.00%

Restructuring Charges and Oth_4

Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Schedule of Acquisitions and Cost-Reduction/Productivity Initiatives (Detail) - USD ($) $ in Millions		Mar. 11, 2022	Apr. 03, 2022	Apr. 04, 2021
Restructuring charges/(credits):
Employee terminations			$ 25	$ 22
Asset impairments			8	(5)
Exit costs/(credits)			11	0
Restructuring charges/(credits)	[1]		43	17
Transaction costs	[2]		6	0
Integration costs and other	[3]		142	5
Restructuring charges and certain acquisition-related costs			192	22
Additional depreciation––asset restructuring	[4]		9	6
Implementation costs	[5]		85	75
Total costs associated with acquisitions and cost-reduction/productivity initiatives			280	111
Other (income)/deductions––net [Member]
Restructuring charges/(credits):
Net periodic benefit costs/(credits) recorded in Other (income)/deductions––net			(6)	8
Cost of sales [Member]
Restructuring charges/(credits):
Implementation costs	[5]		12	11
Selling, informational and administrative expenses [Member]
Restructuring charges/(credits):
Implementation costs	[5]		74	$ 64
Restructuring Charges And Acquisition-Related Costs [Member] | Arena [Member]
Restructuring charges/(credits):
Post closing compensation expense		$ 138	$ 138
[1]	Primarily represents cost reduction initiatives.
[2]	Represents external costs for banking, legal, accounting and other similar services.
[3]	Represents external, incremental costs directly related to integrating acquired businesses, such as expenditures for consulting and the integration of systems and processes, and certain other qualifying costs. In the first quarter of 2022, integration costs and other were mostly related to our acquisition of Arena, including $138 million in payments to Arena employees for the fair value of previously unvested long-term incentive awards. See Note 2A.
[4]	Represents the impact of changes in the estimated useful lives of assets involved in restructuring actions.
[5]	Represents external, incremental costs directly related to implementing our non-acquisition-related cost-reduction/productivity initiatives.

Restructuring Charges and Oth_5

Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Schedule of Components and Changes in Restructuring Accruals (Detail) - USD ($) $ in Millions		3 Months Ended
		Apr. 03, 2022	Apr. 04, 2021
Restructuring Reserve [Roll Forward]
Balance, beginning	[1]	$ 1,071
Provision	[2]	43	$ 17
Utilization and other	[3]	(163)
Balance, ending	[4]	952
Other Current Liabilities [Member]
Restructuring Reserve [Roll Forward]
Balance, beginning		816
Balance, ending		812
Other Noncurrent Liabilities [Member]
Restructuring Reserve [Roll Forward]
Balance, beginning		255
Balance, ending		140
Employee Termination Costs [Member]
Restructuring Reserve [Roll Forward]
Balance, beginning	[1]	1,014
Provision		25
Utilization and other	[3]	(95)
Balance, ending	[4]	943
Asset Impairment Charges [Member]
Restructuring Reserve [Roll Forward]
Balance, beginning	[1]	0
Provision		8
Utilization and other	[3]	(8)
Balance, ending	[4]	0
Exit Costs [Member]
Restructuring Reserve [Roll Forward]
Balance, beginning	[1]	57
Provision		11
Utilization and other	[3]	(59)
Balance, ending	[4]	$ 9
[1]	Included in Other current liabilities ($816 million) and Other noncurrent liabilities ($255 million).
[2]	Primarily represents cost reduction initiatives.
[3]	Includes adjustments for foreign currency translation.
[4]	Included in Other current liabilities ($812 million) and Other noncurrent liabilities ($140 million).

Other (Income)_Deductions - N_3

Other (Income)/Deductions - Net - Schedule of Other (Income)/Deductions - Net (Detail) - USD ($) $ in Millions		3 Months Ended
		Apr. 03, 2022	Apr. 04, 2021
Other Income and Expenses [Abstract]
Interest income		$ (14)	$ 0
Interest expense		322	336
Net interest expense		308	336
Royalty-related income		(173)	(176)
Net (gains)/losses on asset disposals		(1)	(39)
Net (gains)/losses recognized during the period on equity securities	[1],[2]	699	(401)
Income from collaborations, out-licensing arrangements and sales of compound/product rights	[3]	(9)	(231)
Net periodic benefit costs/(credits) other than service costs		(283)	(266)
Certain legal matters, net		79	51
Consumer Healthcare JV equity method (income)/loss	[4]	(184)	(62)
Other, net		(88)	(216)
Other (income)/deductions––net		$ 350	$ (1,004)
[1]	Reported in Other (income)/deductions –– net. See Note 4 .
[2]	The losses in the first quarter of 2022 include, among other things, unrealized losses of $473 million related to our investment in BioNTech. The gains in the first quarter of 2021 included, among other things, unrealized gains of $409 million related to investments in Allogene Therapeutics, Inc. and BioNTech.
[3]	The first quarter of 2021 included, among other things, $188 million of net collaboration income from BioNTech related to Comirnaty.
[4]	See Note 2C

Other (Income)_Deductions - N_4

Other (Income)/Deductions - Net - Footnotes (Detail) - USD ($) $ in Millions		3 Months Ended
		Apr. 03, 2022	Apr. 04, 2021
Loss Contingencies [Line Items]
Unrealized gain (loss) on equity securities	[1]	$ (710)	$ 372
BioNTech [Member]
Loss Contingencies [Line Items]
Unrealized gain (loss) on equity securities		(473)
Allogene and BioNTech [Member]
Loss Contingencies [Line Items]
Unrealized gain (loss) on equity securities			$ 409
BioNTech [Member] | Collaborative Arrangement [Member]
Loss Contingencies [Line Items]
Proceeds from collaborators		$ 188
[1]	Included in net unrealized (gains)/losses are observable price changes on equity securities without readily determinable fair values. As of April 3, 2022, there were cumulative impairments and downward adjustments of $110 million and upward adjustments of $167 million. Impairments, downward and upward adjustments were not significant in the first quarters of 2022 and 2021.

Tax Matters - Narrative (Detail

Tax Matters - Narrative (Detail) - USD ($) $ in Billions	3 Months Ended
	Apr. 03, 2022	Apr. 04, 2021
Income Tax Disclosure [Abstract]
Effective tax rate for income from continuing operations	12.90%	14.20%
Repatriation tax liability	$ 15

Tax Matters - Schedule of Tax P

Tax Matters - Schedule of Tax Provision/(Benefit) on Other Comprehensive Income (Loss) (Detail) - USD ($) $ in Millions		3 Months Ended
		Apr. 03, 2022	Apr. 04, 2021
Income Tax Disclosure [Abstract]
Foreign currency translation adjustments, net	[1]	$ (72)	$ 21
Unrealized holding gains/(losses) on derivative financial instruments, net		32	59
Reclassification adjustments for (gains)/losses included in net income		(22)	34
Derivatives qualifying as hedges, tax, total		10	93
Unrealized holding gains/(losses) on available-for-sale securities, net		(17)	10
Reclassification adjustments for (gains)/losses included in net income		29	(30)
Available-for-sale securities, tax, total		12	(20)
Reclassification adjustments related to amortization of prior service costs and other, net		(9)	(10)
Reclassification adjustments related to curtailments of prior service costs and other, net		(2)	0
Other		0	0
Pension and other postretirement benefit plans, net prior service cost (credit), tax		(11)	(10)
Tax provision/(benefit) on other comprehensive income/(loss)		$ (60)	$ 84
[1]	Taxes are not provided for foreign currency translation adjustments relating to investments in international subsidiaries that we intend to hold indefinitely.

Accumulated Other Comprehensi_3

Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests (Detail) - USD ($) $ in Millions		3 Months Ended
		Apr. 03, 2022		Apr. 04, 2021
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance		$ 77,462		$ 63,473
Other comprehensive income/(loss)		(260)		647
Ending balance		82,685		68,865
Accumulated Other Comprehensive Income (Loss) [Member]
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance		(5,897)		(5,310)
Other comprehensive income/(loss)		(260)	[1]	646
Ending balance		(6,157)		$ (4,664)
Foreign Currency Translation Adjustment [Member]
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance		(6,172)
Other comprehensive income/(loss)	[1]	(291)
Ending balance		(6,463)
Derivative Financial Instruments [Member]
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance		119
Other comprehensive income/(loss)	[1]	(20)
Ending balance		99
Available-For-Sale Securities [Member]
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance		(220)
Other comprehensive income/(loss)	[1]	87
Ending balance		(133)
Prior Service (Costs)/Credits and Other [Member]
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance		377
Other comprehensive income/(loss)	[1]	(36)
Ending balance		$ 341
[1]	Amounts do not include foreign currency translation adjustments attributable to noncontrolling interests. Foreign currency translation adjustments include net losses related to our equity method investment in the Consumer Healthcare JV (see Note 2C ) and the impact of our net investment hedging program.

Financial Instruments - Financi

Financial Instruments - Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Detail) - USD ($) $ in Millions		Apr. 03, 2022	Dec. 31, 2021
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity securities with readily determinable fair values	[1]	$ 2,759	$ 5,365
Total other noncurrent assets		7,879	7,679
Total assets		183,841	181,476
Total liabilities		930	881
Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets		26,020	33,552
Total liabilities		930	881
Long-term equity securities held in trust		155	194
Short-term investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities		17,337	22,014
Total short-term investments		20,096	27,379
Other Current Assets [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Current derivative assets		837	709
Other Current Assets [Member] | Recurring [Member] | Interest rate contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Current derivative assets		5	4
Other Current Assets [Member] | Recurring [Member] | Foreign exchange contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Current derivative assets		832	704
Long-term Investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity securities with readily determinable fair values	[2]	3,486	3,876
Available-for-sale debt securities		569	521
Total long-term investments		4,055	4,397
Other Noncurrent Assets [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Noncurrent derivative assets		267	259
Insurance contracts	[3]	765	808
Total other noncurrent assets		1,032	1,067
Other Noncurrent Assets [Member] | Recurring [Member] | Interest rate contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Noncurrent derivative assets		0	16
Other Noncurrent Assets [Member] | Recurring [Member] | Foreign exchange contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Noncurrent derivative assets		267	242
Other Current Liabilities [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Current derivative liabilities		330	476
Other Current Liabilities [Member] | Recurring [Member] | Foreign exchange contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Current derivative liabilities		330	476
Other Noncurrent Liabilities [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Noncurrent derivative liabilities		600	405
Other Noncurrent Liabilities [Member] | Recurring [Member] | Interest rate contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Noncurrent derivative liabilities		140	0
Other Noncurrent Liabilities [Member] | Recurring [Member] | Foreign exchange contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Noncurrent derivative liabilities		460	405
Level 1 [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets		3,470	3,849
Total liabilities		0	0
Level 1 [Member] | Short-term investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities		0	0
Total short-term investments		0	0
Level 1 [Member] | Other Current Assets [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Current derivative assets		0	0
Level 1 [Member] | Other Current Assets [Member] | Recurring [Member] | Interest rate contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Current derivative assets		0	0
Level 1 [Member] | Other Current Assets [Member] | Recurring [Member] | Foreign exchange contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Current derivative assets		0	0
Level 1 [Member] | Long-term Investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity securities with readily determinable fair values	[2]	3,470	3,849
Available-for-sale debt securities		0	0
Total long-term investments		3,470	3,849
Level 1 [Member] | Other Noncurrent Assets [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Noncurrent derivative assets		0	0
Insurance contracts	[3]	0	0
Total other noncurrent assets		0	0
Level 1 [Member] | Other Noncurrent Assets [Member] | Recurring [Member] | Interest rate contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Noncurrent derivative assets		0	0
Level 1 [Member] | Other Noncurrent Assets [Member] | Recurring [Member] | Foreign exchange contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Noncurrent derivative assets		0	0
Level 1 [Member] | Other Current Liabilities [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Current derivative liabilities		0	0
Level 1 [Member] | Other Current Liabilities [Member] | Recurring [Member] | Foreign exchange contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Current derivative liabilities		0	0
Level 1 [Member] | Other Noncurrent Liabilities [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Noncurrent derivative liabilities		0	0
Level 1 [Member] | Other Noncurrent Liabilities [Member] | Recurring [Member] | Interest rate contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Noncurrent derivative liabilities		0	0
Level 1 [Member] | Other Noncurrent Liabilities [Member] | Recurring [Member] | Foreign exchange contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Noncurrent derivative liabilities		0	0
Level 2 [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets		22,550	29,703
Total liabilities		930	881
Level 2 [Member] | Short-term investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities		17,337	22,014
Total short-term investments		20,096	27,379
Level 2 [Member] | Other Current Assets [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Current derivative assets		837	709
Level 2 [Member] | Other Current Assets [Member] | Recurring [Member] | Interest rate contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Current derivative assets		5	4
Level 2 [Member] | Other Current Assets [Member] | Recurring [Member] | Foreign exchange contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Current derivative assets		832	704
Level 2 [Member] | Long-term Investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity securities with readily determinable fair values	[2]	15	27
Available-for-sale debt securities		569	521
Total long-term investments		584	548
Level 2 [Member] | Other Noncurrent Assets [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Noncurrent derivative assets		267	259
Insurance contracts	[3]	765	808
Total other noncurrent assets		1,032	1,067
Level 2 [Member] | Other Noncurrent Assets [Member] | Recurring [Member] | Interest rate contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Noncurrent derivative assets		0	16
Level 2 [Member] | Other Noncurrent Assets [Member] | Recurring [Member] | Foreign exchange contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Noncurrent derivative assets		267	242
Level 2 [Member] | Other Current Liabilities [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Current derivative liabilities		330	476
Level 2 [Member] | Other Current Liabilities [Member] | Recurring [Member] | Foreign exchange contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Current derivative liabilities		330	476
Level 2 [Member] | Other Noncurrent Liabilities [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Noncurrent derivative liabilities		600	405
Level 2 [Member] | Other Noncurrent Liabilities [Member] | Recurring [Member] | Interest rate contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Noncurrent derivative liabilities		140	0
Level 2 [Member] | Other Noncurrent Liabilities [Member] | Recurring [Member] | Foreign exchange contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Noncurrent derivative liabilities		460	405
Money market funds [Member] | Short-term investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity securities with readily determinable fair values		2,759	5,365
Money market funds [Member] | Level 1 [Member] | Short-term investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity securities with readily determinable fair values		0	0
Money market funds [Member] | Level 2 [Member] | Short-term investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity securities with readily determinable fair values		2,759	5,365
Government and agency - non U.S. [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities		15,067	17,783
Government and agency - non U.S. [Member] | Short-term investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities		14,548	17,318
Government and agency - non U.S. [Member] | Long-term Investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities		519	465
Government and agency - non U.S. [Member] | Level 1 [Member] | Short-term investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities		0	0
Government and agency - non U.S. [Member] | Level 1 [Member] | Long-term Investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities		0	0
Government and agency - non U.S. [Member] | Level 2 [Member] | Short-term investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities		14,548	17,318
Government and agency - non U.S. [Member] | Level 2 [Member] | Long-term Investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities		519	465
Government and agency - U.S. [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities		1,831	4,055
Government and agency - U.S. [Member] | Short-term investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities		1,830	4,050
Government and agency - U.S. [Member] | Long-term Investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities		1	6
Government and agency - U.S. [Member] | Level 1 [Member] | Short-term investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities		0	0
Government and agency - U.S. [Member] | Level 1 [Member] | Long-term Investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities		0	0
Government and agency - U.S. [Member] | Level 2 [Member] | Short-term investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities		1,830	4,050
Government and agency - U.S. [Member] | Level 2 [Member] | Long-term Investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities		1	6
Corporate and other [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities		1,008	697
Corporate and other [Member] | Short-term investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities		958	647
Corporate and other [Member] | Long-term Investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities		49	50
Corporate and other [Member] | Level 1 [Member] | Short-term investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities		0	0
Corporate and other [Member] | Level 1 [Member] | Long-term Investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities		0	0
Corporate and other [Member] | Level 2 [Member] | Short-term investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities		958	647
Corporate and other [Member] | Level 2 [Member] | Long-term Investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities		$ 49	$ 50
[1]	As of April 3, 2022 and December 31, 2021, includes money market funds primarily invested in U.S. Treasury and government debt.
[2]	Long-term equity securities of $155 million as of April 3, 2022 and $194 million as of December 31, 2021 were held in restricted trusts for U.S. non-qualified employee benefit plans.
[3]	Includes life insurance policies held in restricted trusts for U.S. non-qualified employee benefit plans. The underlying invested assets in these contracts are marketable securities, which are carried at fair value, with changes in fair value recognized in Other (income)/deductions—net (see Note 4 ).

Financial Instruments - Finan_2

Financial Instruments - Financial Liabilities Not Measured at Fair Value on a Recurring Basis (Details) - USD ($) $ in Billions	Apr. 03, 2022	Dec. 31, 2021
Carrying Value [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Long-term debt, fair value	$ 36	$ 36
Estimated Fair Value [Member] | Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Long-term debt, fair value	$ 38	$ 42

Financial Instruments - Investm

Financial Instruments - Investments by Classification Type (Details) - USD ($) $ in Millions		Apr. 03, 2022	Dec. 31, 2021
Short-term investments
Equity securities with readily determinable fair values	[1]	$ 2,759	$ 5,365
Available-for-sale debt securities		17,337	22,014
Held-to-maturity debt securities		1,331	1,746
Short-term investments		21,427	29,125
Long-term investments
Equity securities with readily determinable fair values		3,486	3,876
Available-for-sale debt securities		569	521
Held-to-maturity debt securities		41	34
Private equity securities at cost	[2]	647	623
Total Long-term investments		4,742	5,054
Equity-method investments		15,995	16,472
Total long-term investments and equity-method investments		20,737	21,526
Held-to-maturity cash equivalents		$ 458	$ 268
[1]	As of April 3, 2022 and December 31, 2021, includes money market funds primarily invested in U.S. Treasury and government debt.
[2]	Represent investments in the life sciences sector

Financial Instruments - Schedul

Financial Instruments - Schedule of Investment Securities (Details) - USD ($) $ in Millions	Apr. 03, 2022	Dec. 31, 2021
Debt Securities, Held-to-maturity, Maturity, Fair Value [Abstract]
Debt securities, amortized cost	$ 19,887	$ 24,835
Debt securities, gross unrealized gains	8	14
Debt securities, gross unrealized losses	(160)	(265)
Debt securities, fair value	19,735	24,584
Debt securities maturities, within 1 year, fair value	19,125
Debt securities maturities, over 1 to 5 years, fair value	598
Debt securities maturities, over 5 years, fair value	12
Time deposits and other [Member]
Debt Securities, Held-to-maturity, Maturity [Abstract]
Held-to-maturity securities, amortized cost	1,015	947
Held-to-maturity securities, gross unrealized gains	0	0
Held-to-maturity securities, gross unrealized losses	0	0
Held-to-maturity securities, fair value	1,015	947
Debt Securities, Held-to-maturity, Maturity, Fair Value [Abstract]
Held-to-maturity securities, debt maturities, within 1 year, fair value	979
Held-to-maturity securities, debt maturities, over 1 to 5 years, fair value	25
Held-to-maturity securities, debt maturities, over 5 years, fair value	11
Held-to-maturity securities, amortized cost	1,015	947
Government and agency - non U.S. [Member]
Debt Securities, Available-for-sale, Fair Value to Amortized Cost [Abstract]
Available-for-sale debt securities, amortized cost	15,217	18,032
Available-for-sale debt securities, gross unrealized gains	8	13
Available-for-sale debt securities, gross unrealized losses	(158)	(263)
Available-for-sale debt securities	15,067	17,783
Available-for-sale Securities, Debt Maturities [Abstract]
Available-for-sale securities, debt maturities, within 1 year, fair value	14,548
Available-for-sale securities, debt maturities, over 1 to 5 years, fair value	519
Available-for-sale securities, debt maturities, over 5 years, fair value	0
Available-for-sale debt securities, fair value	15,067	17,783
Debt Securities, Held-to-maturity, Maturity [Abstract]
Held-to-maturity securities, amortized cost	814	1,102
Held-to-maturity securities, gross unrealized gains	0	0
Held-to-maturity securities, gross unrealized losses	0	0
Held-to-maturity securities, fair value	814	1,102
Debt Securities, Held-to-maturity, Maturity, Fair Value [Abstract]
Held-to-maturity securities, debt maturities, within 1 year, fair value	809
Held-to-maturity securities, debt maturities, over 1 to 5 years, fair value	4
Held-to-maturity securities, debt maturities, over 5 years, fair value	1
Held-to-maturity securities, amortized cost	814	1,102
Government and agency - U.S. [Member]
Debt Securities, Available-for-sale, Fair Value to Amortized Cost [Abstract]
Available-for-sale debt securities, amortized cost	1,832	4,056
Available-for-sale debt securities, gross unrealized gains	0	0
Available-for-sale debt securities, gross unrealized losses	(1)	(1)
Available-for-sale debt securities	1,831	4,055
Available-for-sale Securities, Debt Maturities [Abstract]
Available-for-sale securities, debt maturities, within 1 year, fair value	1,830
Available-for-sale securities, debt maturities, over 1 to 5 years, fair value	1
Available-for-sale securities, debt maturities, over 5 years, fair value	0
Available-for-sale debt securities, fair value	1,831	4,055
Corporate and other [Member]
Debt Securities, Available-for-sale, Fair Value to Amortized Cost [Abstract]
Available-for-sale debt securities, amortized cost	1,009	698
Available-for-sale debt securities, gross unrealized gains	0	0
Available-for-sale debt securities, gross unrealized losses	(1)	(1)
Available-for-sale debt securities	1,008	697
Available-for-sale Securities, Debt Maturities [Abstract]
Available-for-sale securities, debt maturities, within 1 year, fair value	958
Available-for-sale securities, debt maturities, over 1 to 5 years, fair value	49
Available-for-sale securities, debt maturities, over 5 years, fair value	0
Available-for-sale debt securities, fair value	$ 1,008	$ 697

Financial Instruments - Inves_2

Financial Instruments - Investments - Unrealized Gains and Losses Related to Equity Securities (Details) - USD ($) $ in Millions		3 Months Ended
		Apr. 03, 2022	Apr. 04, 2021
Fair Value Disclosures [Abstract]
Net (gains)/losses recognized during the period on equity securities	[1],[2]	$ 699	$ (401)
Less: Net (gains)/losses recognized during the period on equity securities sold during the period		(11)	(28)
Net unrealized (gains)/losses during the reporting period on equity securities still held at the reporting date	[3]	$ 710	$ (372)
[1]	Reported in Other (income)/deductions –– net. See Note 4 .
[2]	The losses in the first quarter of 2022 include, among other things, unrealized losses of $473 million related to our investment in BioNTech. The gains in the first quarter of 2021 included, among other things, unrealized gains of $409 million related to investments in Allogene Therapeutics, Inc. and BioNTech.
[3]	Included in net unrealized (gains)/losses are observable price changes on equity securities without readily determinable fair values. As of April 3, 2022, there were cumulative impairments and downward adjustments of $110 million and upward adjustments of $167 million. Impairments, downward and upward adjustments were not significant in the first quarters of 2022 and 2021.

Financial Instruments - Inves_3

Financial Instruments - Investments - Unrealized Gains and Losses Related to Equity Securities - Footnotes (Details) $ in Millions	Apr. 03, 2022USD ($)
Fair Value Disclosures [Abstract]
Cumulative impairment losses and downward price adjustments on equity securities	$ 110
Cumulative upward price adjustments on equity securities	$ 167

Financial Instruments - Short-t

Financial Instruments - Short-term Borrowings (Details) - USD ($) $ in Millions		Apr. 03, 2022	Dec. 31, 2021
Fair Value Disclosures [Abstract]
Current portion of long-term debt, principal amount		$ 251	$ 1,636
Other short-term borrowings, principal amount	[1]	385	605
Total short-term borrowings, principal amount		636	2,241
Net fair value adjustments related to hedging and purchase accounting		9	0
Total Short-term borrowings, including current portion of long-term debt, carried at historical proceeds, as adjusted		$ 645	$ 2,241
[1]	Primarily includes cash collateral. See Note 7F .

Financial Instruments - Long-Te

Financial Instruments - Long-Term Debt (Details) - USD ($) $ in Millions	Apr. 03, 2022	Dec. 31, 2021
Debt Instrument [Line Items]
Net fair value adjustments related to hedging and purchase accounting	$ 9	$ 0
Total long-term debt, carried at historical proceeds, as adjusted	35,656	36,195
Current portion of long-term debt, carried at historical proceeds, as adjusted (not included above)	260	1,636
Unsecured Debt [Member]
Debt Instrument [Line Items]
Total long-term debt, principal amount	34,603	34,948
Net fair value adjustments related to hedging and purchase accounting	1,240	1,438
Net unamortized discounts, premiums and debt issuance costs	(190)	(195)
Other long-term debt	3	4
Total long-term debt, carried at historical proceeds, as adjusted	35,656	36,195
Current portion of long-term debt, carried at historical proceeds, as adjusted (not included above)	$ 260	$ 1,636

Financial Instruments - Derivat

Financial Instruments - Derivative Narrative (Details)	3 Months Ended
	Apr. 03, 2022
Foreign exchange contracts [Member]
Derivative [Line Items]
Derivative term of contract	2 years

Financial Instruments - Fair Va

Financial Instruments - Fair Value of Derivative Financial Instruments and Related Notional Amounts (Details) - USD ($) $ in Millions		Apr. 03, 2022	Dec. 31, 2021
Derivative [Line Items]
Asset		$ 1,104	$ 968
Liability		930	881
Derivatives designated as hedging instruments [Member]
Derivative [Line Items]
Asset		904	808
Liability		787	717
Derivatives designated as hedging instruments [Member] | Foreign exchange contracts [Member]
Derivative [Line Items]
Notional	[1]	29,833	29,576
Asset	[1]	899	787
Liability	[1]	647	717
Derivatives designated as hedging instruments [Member] | Interest rate contracts [Member]
Derivative [Line Items]
Notional		2,250	2,250
Asset		5	21
Liability		140	0
Derivatives not designated as hedging instruments [Member] | Foreign exchange contracts [Member]
Derivative [Line Items]
Notional		22,009	21,419
Asset		200	160
Liability		143	164
Inventory sales [Member] | Derivatives designated as hedging instruments [Member] | Foreign exchange contracts [Member]
Derivative [Line Items]
Notional	[1]	$ 4,700	$ 4,800
[1]	The notional amount of outstanding foreign exchange contracts hedging our intercompany forecasted inventory sales was $4.7 billion as of April 3, 2022 and $4.8 billion as of December 31, 2021.

Financial Instruments - Deriv_2

Financial Instruments - Derivative Financial Instruments and Hedging Activities (Details) - USD ($) $ in Millions		3 Months Ended
		Apr. 03, 2022	Apr. 04, 2021
Derivative [Line Items]
Amount of Gains/(Losses) Recognized in OCI		$ 203	$ 214
Amount of Gains/(Losses) Recognized in OCI	[1]	436	460
Amount of Gains/(Losses) Reclassified from OCI into OID and COS	[2]	213	(259)
OID [Member]
Derivative [Line Items]
Amount of Gains/(Losses) Recognized in OID	[1]	(19)	42
Other (Income) Deductions And Cost Of Sales [Member]
Derivative [Line Items]
Amount of Gains/(Losses) Reclassified from OCI into OID and COS	[1]	243	(230)
Designated as Hedging Instrument [Member] | Foreign exchange contracts [Member]
Derivative [Line Items]
Amount of Gains/(Losses) Recognized in OCI	[1],[3]	187	202
Amount of Gains/(Losses) Recognized in OCI	[1]	259	154
Designated as Hedging Instrument [Member] | Foreign currency short-term borrowings [Member]
Derivative [Line Items]
Amount of Gains/(Losses) Recognized in OCI	[1],[4]	26	38
Designated as Hedging Instrument [Member] | Foreign currency debt [Member]
Derivative [Line Items]
Amount of Gains/(Losses) Recognized in OCI	[1],[4]	23	56
Designated as Hedging Instrument [Member] | OID [Member] | Interest rate contracts [Member]
Derivative [Line Items]
Amount of Gains/(Losses) Recognized in OID	[1]	(156)	(26)
Hedged item	[1]	156	26
Designated as Hedging Instrument [Member] | Other (Income) Deductions And Cost Of Sales [Member] | Foreign exchange contracts [Member]
Derivative [Line Items]
Amount of Gains/(Losses) Reclassified from OCI into OID and COS	[1],[3]	195	(268)
Amount of Gains/(Losses) Reclassified from OCI into OID and COS	[1]	0	0
Designated as Hedging Instrument [Member] | Other (Income) Deductions And Cost Of Sales [Member] | Foreign currency short-term borrowings [Member]
Derivative [Line Items]
Amount of Gains/(Losses) Reclassified from OCI into OID and COS	[1],[4]	0	0
Designated as Hedging Instrument [Member] | Other (Income) Deductions And Cost Of Sales [Member] | Foreign currency debt [Member]
Derivative [Line Items]
Amount of Gains/(Losses) Reclassified from OCI into OID and COS	[1],[4]	0	0
Derivative Financial Instruments Not Designated as Hedges [Member] | OID [Member] | Foreign exchange contracts [Member]
Derivative [Line Items]
Amount of Gains/(Losses) Recognized in OID	[1]	(19)	42
Cash Flow Hedging [Member] | Designated as Hedging Instrument [Member] | Foreign exchange contracts [Member]
Derivative [Line Items]
Amount excluded from effectiveness testing and amortized into earnings	[1],[5]	16	12
Cash Flow Hedging [Member] | Designated as Hedging Instrument [Member] | Other (Income) Deductions And Cost Of Sales [Member] | Foreign exchange contracts [Member]
Derivative [Line Items]
Amount excluded from effectiveness testing	[1],[5]	18	9
Net Investment Hedging [Member] | Designated as Hedging Instrument [Member] | Foreign exchange contracts [Member]
Derivative [Line Items]
Amount excluded from effectiveness testing and amortized into earnings	[1],[5]	(74)	(1)
Net Investment Hedging [Member] | Designated as Hedging Instrument [Member] | Other (Income) Deductions And Cost Of Sales [Member] | Foreign exchange contracts [Member]
Derivative [Line Items]
Amount excluded from effectiveness testing	[1],[5]	$ 30	$ 29
[1]	OID = Other (income)/deductions—net, included in Other (income)/deductions—net in the condensed consolidated statements of income . COS = Cost of Sales, included in Cost of sales in the condensed consolidated statements of income. OCI = Other comprehensive income/(loss), included in the condensed consolidated statements of comprehensive income
[2]	Reclassified into Other (income)/deductions—net and Cost of sales. See Note 7E.
[3]	The amounts reclassified from OCI into COS were: • a net gain of $34 million in the first quarter of 2022; and • a net loss of $45 million in the first quarter of 2021. The remaining amounts were reclassified from OCI into OID. Based on quarter-end foreign exchange rates that are subject to change, we expect to reclassify a pre-tax gain of $332 million within the next 12 months into income . The maximum length of time over which we are hedging our exposure to the variability in future foreign exchange cash flows is approximately 21 years and relates to foreign currency debt.
[4]	Short-term borrowings and long-term debt include foreign currency borrowings which are used in net investment hedges. The short-term borrowings’ carrying value as of December 31, 2021 was $1.1 billion. The long-term debt carrying values as of April 3, 2022 and December 31, 2021 were $821 million and $844 million, respectively.
[5]	The amounts reclassified from OCI were reclassified into OID.

Financial Instruments - Deriv_3

Financial Instruments - Derivative Financial Instruments and Hedging Activities - Footnotes (Details) - USD ($) $ in Millions		3 Months Ended
		Apr. 03, 2022	Apr. 04, 2021	Dec. 31, 2021
Derivative [Line Items]
Amount of Gains/(Losses) Reclassified from OCI into OID and COS	[1]	$ 213	$ (259)
Pre-tax gain expected to be reclassified within the next 12 months		332
Short-term borrowings		645		$ 2,241
Foreign currency debt [Member]
Derivative [Line Items]
Short-term borrowings				1,100
Long-term debt		$ 821		$ 844
Designated as Hedging Instrument [Member] | Foreign exchange contracts [Member]
Derivative [Line Items]
Remaining period of hedging exposure		21 years
Designated as Hedging Instrument [Member] | Cost of sales [Member] | Foreign exchange contracts [Member]
Derivative [Line Items]
Amount of Gains/(Losses) Reclassified from OCI into OID and COS		$ 34	$ (45)
[1]	Reclassified into Other (income)/deductions—net and Cost of sales. See Note 7E.

Financial Instruments - Cumulat

Financial Instruments - Cumulative Basis Adjustments for Fair Value Hedges (Details) - USD ($) $ in Millions		Apr. 03, 2022	Dec. 31, 2021
Short-term Debt [Member]
Derivative [Line Items]
Carrying Amount of Actively Hedged Liabilities	[1]	$ 0	$ 0
Cumulative Amount of Fair Value Hedging Adjustment Increase/(Decrease) to Carrying Amount, Active Hedging Relationships, Liability		0	0
Cumulative Amount of Fair Value Hedging Adjustment Increase/(Decrease) to Carrying Amount, Discontinued Hedging Relationships, Liability		4	0
Long-term debt [Member]
Derivative [Line Items]
Carrying Amount of Actively Hedged Liabilities	[1]	2,234	2,233
Cumulative Amount of Fair Value Hedging Adjustment Increase/(Decrease) to Carrying Amount, Active Hedging Relationships, Liability		(140)	16
Cumulative Amount of Fair Value Hedging Adjustment Increase/(Decrease) to Carrying Amount, Discontinued Hedging Relationships, Liability		$ 1,124	$ 1,154
[1]	Carrying amounts exclude the cumulative amount of fair value hedging adjustments.

Financial Instruments - Credit

Financial Instruments - Credit Risk (Details) $ in Millions	Apr. 03, 2022USD ($)
Financial Instruments [Abstract]
Derivatives in a net liability position	$ 568
Collateral posted	526
Derivatives in a net receivable position	532
Collateral received	$ 341

Other Financial Information - I

Other Financial Information - Inventories (Details) - USD ($) $ in Millions		Apr. 03, 2022	Dec. 31, 2021
Other Financial Information [Abstract]
Finished goods		$ 3,633	$ 3,641
Work-in-process		4,843	4,424
Raw materials and supplies		1,502	994
Inventories	[1]	9,979	9,059
Noncurrent inventories not included above	[2]	$ 894	$ 939
[1]	The change from December 31, 2021 reflects increases for Paxlovid and Comirnaty, as well as increases for certain products mainly for network strategy and supply recovery, partially offset by decreases due to market demand.
[2]	Included in Other noncurrent assets . There are no recoverability issues for these amounts.

Other Financial Information - O

Other Financial Information - Other Current Liabilities (Details) - USD ($) $ in Millions	Apr. 03, 2022	Dec. 31, 2021
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Other current liabilities	$ 24,583	$ 24,939
BioNTech [Member] | Comirnaty direct sales and alliance revenues [Member] | Collaborative Arrangement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Other current liabilities	$ 10,000	$ 9,700

Identifiable Intangible Asset_2

Identifiable Intangible Assets - Finite-lived and Indefinite-lived Intangible Assets (Detail) - USD ($) $ in Millions		Apr. 03, 2022	Dec. 31, 2021
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, gross carrying amount		$ 76,436	$ 76,552
Finite-lived intangible assets, accumulated amortization	[1],[2]	(56,542)	(55,838)
Finite-lived intangible assets, net		19,894	20,714
Indefinite-lived Intangible Assets [Line Items]
Indefinite-lived intangible assets		9,922	4,432
Intangible assets, gross carrying amount	[1],[2]	86,358	80,984
Finite-lived intangible assets, accumulated amortization	[1],[2]	(56,542)	(55,838)
Identifiable Intangible Assets, less Accumulated Amortization	[1],[2]	29,816	25,146
Brands [Member]
Indefinite-lived Intangible Assets [Line Items]
Indefinite-lived intangible assets		827	827
IPR&D [Member]
Indefinite-lived Intangible Assets [Line Items]
Indefinite-lived intangible assets	[1]	8,122	3,092
License Agreements and Other [Member]
Indefinite-lived Intangible Assets [Line Items]
Indefinite-lived intangible assets	[1]	973	513
Developed technology rights [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, gross carrying amount		73,212	73,346
Finite-lived intangible assets, accumulated amortization		(54,397)	(53,732)
Finite-lived intangible assets, net		18,815	19,614
Indefinite-lived Intangible Assets [Line Items]
Finite-lived intangible assets, accumulated amortization		(54,397)	(53,732)
Brands [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, gross carrying amount		922	922
Finite-lived intangible assets, accumulated amortization		(816)	(807)
Finite-lived intangible assets, net		106	115
Indefinite-lived Intangible Assets [Line Items]
Finite-lived intangible assets, accumulated amortization		(816)	(807)
License Agreements and Other [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, gross carrying amount		2,302	2,284
Finite-lived intangible assets, accumulated amortization		(1,329)	(1,299)
Finite-lived intangible assets, net		973	985
Indefinite-lived Intangible Assets [Line Items]
Finite-lived intangible assets, accumulated amortization		$ (1,329)	$ (1,299)
[1]	The increase in the gross carrying amounts mainly reflect the impact of the acquisition of Arena. See Note 2A .
[2]	The increase is primarily due to the acquisition of Arena, partially offset by amortization expense.

Identifiable Intangible Asset_3

Identifiable Intangible Assets - Goodwill (Detail) $ in Millions	3 Months Ended
	Apr. 03, 2022USD ($)	[1]
Goodwill [Roll Forward]
Balance, beginning	$ 49,208
Additions	1,023	[2]
Other	(21)	[3]
Balance, ending	$ 50,211
[1]	All goodwill is assigned within the Biopharma reportable segment.
[2]	Additions relate to our acquisition of Arena. See Note 2A .
[3]	Other represents the impact of foreign exchange.

Pension and Postretirement Be_3

Pension and Postretirement Benefit Plans - Net Periodic Benefit Cost (Detail) - USD ($) $ in Millions		3 Months Ended
		Apr. 03, 2022	Apr. 04, 2021
Pension Plan [Member] | U.S. [Member]
Defined Benefit Plan Disclosure [Line Items]
Service cost		$ 0	$ 0
Interest cost		118	113
Expected return on plan assets		(245)	(261)
Amortization of prior service credits		0	(1)
Actuarial (gains)/losses	[1]	(65)	(47)
Curtailments		0	0
Special termination benefits		6	7
Net periodic benefit cost/(credit) reported in income		(186)	(187)
Pension Plan [Member] | International [Member]
Defined Benefit Plan Disclosure [Line Items]
Service cost		30	33
Interest cost		42	36
Expected return on plan assets		(79)	(82)
Amortization of prior service credits		0	0
Actuarial (gains)/losses	[1]	0	0
Curtailments		0	0
Special termination benefits		0	0
Net periodic benefit cost/(credit) reported in income		(8)	(12)
Postretirement Plans [Member]
Defined Benefit Plan Disclosure [Line Items]
Service cost		7	9
Interest cost		7	7
Expected return on plan assets		(12)	(10)
Amortization of prior service credits		(36)	(39)
Actuarial (gains)/losses	[1]	0	0
Curtailments		(13)	0
Special termination benefits		0	1
Net periodic benefit cost/(credit) reported in income		$ (46)	$ (32)
[1]	Mainly reflects interim actuarial remeasurement gains in 2022, primarily due to an increase in the discount rate.

Pension and Postretirement Be_4

Pension and Postretirement Benefit Plans - Narrative (Detail) $ in Millions	3 Months Ended
	Apr. 03, 2022USD ($)
Pension Plan [Member] | U.S. [Member]
Defined Benefit Plan Disclosure [Line Items]
Contributions by employer	$ 112
Pension Plan [Member] | International [Member]
Defined Benefit Plan Disclosure [Line Items]
Contributions by employer	49
Postretirement Plans [Member]
Defined Benefit Plan Disclosure [Line Items]
Contributions by employer	$ 3

Earnings Per Common Share Att_3

Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders (Details) - USD ($) shares in Millions, $ in Millions		3 Months Ended
		Apr. 03, 2022	Apr. 04, 2021
EPS Numerator––Basic
Income from continuing operations attributable to Pfizer Inc. common shareholders		$ 7,872	$ 4,876
Discontinued operations––net of tax		(9)	1
Net income attributable to Pfizer Inc. common shareholders		7,864	4,877
EPS Numerator––Diluted
Income from continuing operations attributable to Pfizer Inc. common shareholders and assumed conversions		7,872	4,876
Discontinued operations––net of tax, attributable to Pfizer Inc. common shareholders and assumed conversions		(9)	1
Net income attributable to Pfizer Inc. common shareholders and assumed conversions		$ 7,864	$ 4,877
EPS Denominator
Weighted-average number of common shares outstanding––Basic		5,617	5,584
Common-share equivalents: stock options and stock issuable under employee compensation plans (in shares)		141	78
Weighted-average number of common shares outstanding––Diluted		5,758	5,662
Anti-dilutive common stock equivalents (in shares)	[1]	0	2
[1]	These common stock equivalents were outstanding for the periods presented, but were not included in the computation of diluted EPS for those periods because their inclusion would have had an anti-dilutive effect.

Contingencies and Certain Com_2

Contingencies and Certain Commitments (Patent Litigation) (Details) $ in Millions	3 Months Ended	12 Months Ended
	Apr. 03, 2022USD ($)patent	Dec. 31, 2017patentdefendant
Gain Contingencies [Line Items]
Threshold for disclosure of proceedings under environmental laws | $	$ 1
Pneumococcal Vaccine Patent Infringement [Member]
Gain Contingencies [Line Items]
Number of patents without court proceedings		2
Number of patents allegedly infringed upon	2
Other Patent Infringement [Member]
Gain Contingencies [Line Items]
Number of patents allegedly infringed upon	1
Eliquis [Member] | Pfizer and BMS Versus Several Generic Manufacturers [Member] | Patent Infringement [Member] | Pending Litigation [Member]
Gain Contingencies [Line Items]
Number of defendants | defendant		25
Number of patents allegedly infringed upon, expired December 2019		1
Number of patents allegedly infringed upon		3

Contingencies and Certain Com_3

Contingencies and Certain Commitments (Product Litigation, Commercial and Other Matters, Legal Proceedings) (Details)	1 Months Ended	12 Months Ended
	Sep. 30, 2021lagoon	Dec. 31, 2018lagoonmanufacturer	Dec. 31, 2013lagoon
Pfizer And Hospira And Various Other Manufacturers Versus Mississippi Attorney General [Member] | Docetaxel [Member] | Pending Litigation [Member]
Loss Contingencies [Line Items]
Number of defendants other than main defendant | manufacturer		8
Environmental Remediation Litigation [Member]
Loss Contingencies [Line Items]
Feasibility study, number of lagoons | lagoon	2	2	2

Segment, Geographic and Other_3

Segment, Geographic and Other Revenue Information - Narrative (Detail)	3 Months Ended
	Apr. 03, 2022USD ($)operatingSegment	Dec. 31, 2021USD ($)
Segment Reporting Information [Line Items]
Number of segments | operatingSegment	2
Total assets	$ 183,841,000,000	$ 181,476,000,000
Remaining performance obligation	30,000,000,000
Deferred revenues, current	3,108,000,000	3,067,000,000
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-04-01
Segment Reporting Information [Line Items]
Remaining performance obligation	$ 18,000,000,000
Remaining performance obligation, period of recognition	9 months
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01
Segment Reporting Information [Line Items]
Remaining performance obligation	$ 12,000,000,000
Remaining performance obligation, period of recognition	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01
Segment Reporting Information [Line Items]
Remaining performance obligation	$ 300,000,000
Remaining performance obligation, period of recognition	1 year
U.S. Government [Member] | Comirnaty and Paxlovid [Member]
Segment Reporting Information [Line Items]
Deferred revenues	$ 3,300,000,000
Deferred revenues, current	3,000,000,000
Deferred revenues, noncurrent	258,000,000
U.S. Government [Member] | Comirnaty [Member]
Segment Reporting Information [Line Items]
Deferred revenues		3,300,000,000
Deferred revenues, current		3,000,000,000
Deferred revenues, noncurrent		249,000,000
Deferred revenue recognized	$ 1,600,000,000
U.S. Government [Member] | Paxlovid [Member]
Segment Reporting Information [Line Items]
Deferred revenues		$ 0
Customer Concentration Risk [Member] | Revenue Benchmark [Member] | U.S. Government [Member] | Comirnaty and Paxlovid [Member]
Segment Reporting Information [Line Items]
Concentration risk	19.00%
Credit Concentration Risk [Member] | Trade Accounts Receivable [Member] | U.S. Government [Member] | Comirnaty and Paxlovid [Member]
Segment Reporting Information [Line Items]
Concentration risk	11.00%

Segment, Geographic and Other_4

Segment, Geographic and Other Revenue Information - Schedule of Segment Reporting Information by Segment (Details) - USD ($) $ in Millions		3 Months Ended
		Apr. 03, 2022	Apr. 04, 2021
Segment Reporting Information [Line Items]
Revenues	[1]	$ 25,661	$ 14,516
Income from continuing operations before provision/(benefit) for taxes on income	[2]	9,050	5,692
Net gains/(losses) recognized during the period on equity securities	[3],[4]	(699)	401
ViiV [Member]
Segment Reporting Information [Line Items]
Dividend income		56	27
Other Business Activities [Member]
Segment Reporting Information [Line Items]
Revenues	[5]	338	391
Income from continuing operations before provision/(benefit) for taxes on income	[2],[5]	(2,475)	(2,048)
Reconciling Items [Member] | Amortization of Intangible Assets [Member]
Segment Reporting Information [Line Items]
Revenues		0	0
Income from continuing operations before provision/(benefit) for taxes on income	[2]	(835)	(870)
Reconciling Items [Member] | Acquisition-Related Items [Member]
Segment Reporting Information [Line Items]
Revenues		0	0
Income from continuing operations before provision/(benefit) for taxes on income	[2]	(187)	61
Reconciling Items [Member] | Certain Significant Items [Member]
Segment Reporting Information [Line Items]
Revenues	[6]	0	0
Income from continuing operations before provision/(benefit) for taxes on income	[2],[6]	(891)	166
Net gains/(losses) recognized during the period on equity securities		(698)	399
Biopharma [Member]
Segment Reporting Information [Line Items]
Revenues	[1],[7]	25,323	14,125
Biopharma [Member] | Operating Segments [Member]
Segment Reporting Information [Line Items]
Revenues		25,323	14,125
Income from continuing operations before provision/(benefit) for taxes on income	[2]	$ 13,438	$ 8,383
[1]	On December 31, 2021, we completed the sale of our Meridian subsidiary. Prior to its sale, Meridian was managed as part of the Hospital therapeutic area. Beginning in the fourth quarter of 2021, the financial results of Meridian were reflected as discontinued operations. Prior-period financial information has been restated, as appropriate. See Note 1A .
[2]	I ncome from continuing operations before provision/(benefit) for taxes on income. Biopharma’s earnings include dividend income from our investment in ViiV of $56 million in the first quarter of 2022 and $27 million in the first quarter of 2021.
[3]	Reported in Other (income)/deductions –– net. See Note 4 .
[4]	The losses in the first quarter of 2022 include, among other things, unrealized losses of $473 million related to our investment in BioNTech. The gains in the first quarter of 2021 included, among other things, unrealized gains of $409 million related to investments in Allogene Therapeutics, Inc. and BioNTech.
[5]	Other business activities include revenues and costs associated with PC1, as well as costs that we do not allocate to our operating segments, per above.
[6]	Certain significant items are substantive and/or unusual, and in some cases recurring, items (as noted above). For earnings in the first quarter of 2022, includes, among other items, net losses on equity securities of $698 million recorded in Other (income)/deductions––net. For earnings in the first quarter of 2021, includes, among other items, net gains on equity securities of $399 million recorded in Other (income)/deductions––net .
[7]	At the beginning of our fiscal fourth quarter of 2021, we reorganized our commercial operations and began to manage our commercial operations through a new global structure consisting of two operating segments, each led by a single manager: Biopharma, our innovative science-based biopharmaceutical business, and PC1. PC1, which previously had been managed within the Hospital therapeutic area, includes revenues from our contract manufacturing, including certain Comirnaty-related manufacturing activities performed on behalf of BioNTech ($47 million for the first quarter of 2022), and revenues from our active pharmaceutical ingredient sales operation, as well as revenues related to our manufacturing and supply agreements with former legacy Pfizer businesses/partnerships, including but not limited to, transitional manufacturing and supply agreements with Viatris following the spin-off of the Upjohn Business. We have revised prior period information to conform to the current management structure.

Segment, Geographic and Other_5

Segment, Geographic and Other Revenue Information - Revenues By Geographic Area (Detail) - USD ($) $ in Millions		3 Months Ended
		Apr. 03, 2022	Apr. 04, 2021
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	[1]	$ 25,661	$ 14,516
Percentage change in revenue		77.00%
U.S. [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues		$ 8,918	7,530
Percentage change in revenue		18.00%
Developed Europe [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues		$ 6,090	3,038
Percentage change in revenue		100.00%
Developed Rest Of World [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues		$ 3,286	1,123
Percentage change in revenue		193.00%
Emerging Markets [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues		$ 7,367	$ 2,824
Percentage change in revenue		161.00%
[1]	On December 31, 2021, we completed the sale of our Meridian subsidiary. Prior to its sale, Meridian was managed as part of the Hospital therapeutic area. Beginning in the fourth quarter of 2021, the financial results of Meridian were reflected as discontinued operations. Prior-period financial information has been restated, as appropriate. See Note 1A .

Segment, Geographic and Other_6

Segment, Geographic and Other Revenue Information - Revenues By Products (Detail) $ in Millions		3 Months Ended
		Apr. 03, 2022USD ($)operatingSegment	Apr. 04, 2021USD ($)
Revenue from External Customer [Line Items]
Revenues	[1]	$ 25,661	$ 14,516
Number of segments | operatingSegment		2
Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues	[1],[2]	$ 25,323	14,125
Pfizer CentreOne [Member]
Revenue from External Customer [Line Items]
Revenues	[2]	338	391
BioNTech [Member] | Pfizer CentreOne [Member]
Revenue from External Customer [Line Items]
Revenues		47
Total Alliance revenues [Member]
Revenue from External Customer [Line Items]
Revenues		2,314	1,770
Total Biosimilars [Member]
Revenue from External Customer [Line Items]
Revenues	[3]	605	530
Total Sterile Injectable Pharmaceuticals [Member]
Revenue from External Customer [Line Items]
Revenues	[4]	1,331	1,482
Vaccines [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		14,941	4,894
Vaccines [Member] | Comirnaty direct sales and alliance revenues [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		13,227	3,462
Vaccines [Member] | Prevnar Family [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues	[5]	1,565	1,284
Vaccines [Member] | Nimenrix [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		77	46
Vaccines [Member] | FSME/IMMUN-TicoVac [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		42	53
Vaccines [Member] | All other Vaccines [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		29	49
Hospital [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues	[1]	3,191	1,886
Hospital [Member] | Paxlovid [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		1,470	0
Hospital [Member] | Sulperazon [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		210	192
Hospital [Member] | Zithromax [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		125	89
Hospital [Member] | IVIg Products [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues	[6]	107	105
Hospital [Member] | Zavicefta [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		104	94
Hospital [Member] | Medrol [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		76	99
Hospital [Member] | Fragmin [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		70	71
Hospital [Member] | Vfend [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		65	80
Hospital [Member] | All other Anti-infectives [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		381	455
Hospital [Member] | All other Hospital [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		583	700
Oncology [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		2,967	2,862
Oncology [Member] | Ibrance [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		1,237	1,254
Oncology [Member] | Xtandi alliance revenues [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		268	267
Oncology [Member] | Inlyta [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		234	229
Oncology [Member] | Zirabev [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues	[3]	147	86
Oncology [Member] | Bosulif [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		128	123
Oncology [Member] | Xalkori [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		127	134
Oncology [Member] | Ruxience [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues	[3]	124	98
Oncology [Member] | Retacrit [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues	[3]	115	109
Oncology [Member] | Sutent [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		114	200
Oncology [Member] | Lorbrena [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		72	60
Oncology [Member] | Bavencio Alliance Revenues [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		67	32
Oncology [Member] | Aromasin [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		62	52
Oncology [Member] | Trazimera [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues	[3]	52	45
Oncology [Member] | Besponsa [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		51	50
Oncology [Member] | Braftovi [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		48	47
Oncology [Member] | Mektovi [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		40	35
Oncology [Member] | All other Oncology [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		81	41
Internal Medicine [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		2,440	2,594
Internal Medicine [Member] | Eliquis [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		1,793	1,643
Internal Medicine [Member] | Premarin family [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		102	143
Internal Medicine [Member] | BMP2 [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		67	49
Internal Medicine [Member] | Toviaz [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		54	57
Internal Medicine [Member] | Chantix / Champix [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		2	217
Internal Medicine [Member] | All other Internal Medicine [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		423	484
Rare Disease [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		963	824
Rare Disease [Member] | Vyndaqel/Vyndamax [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		612	453
Rare Disease [Member] | BeneFIX [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		112	112
Rare Disease [Member] | Genotropin [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		80	80
Rare Disease [Member] | Somavert [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		68	65
Rare Disease [Member] | ReFacto AF/Xyntha [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		66	89
Rare Disease [Member] | All other Rare Disease [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		25	26
Inflammation and Immunology (I&I) [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		821	1,065
Inflammation and Immunology (I&I) [Member] | Xeljanz [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		372	538
Inflammation and Immunology (I&I) [Member] | Enbrel [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		280	319
Inflammation and Immunology (I&I) [Member] | Inflectra [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues	[3]	135	177
Inflammation and Immunology (I&I) [Member] | All other I & I [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		$ 35	$ 31
[1]	On December 31, 2021, we completed the sale of our Meridian subsidiary. Prior to its sale, Meridian was managed as part of the Hospital therapeutic area. Beginning in the fourth quarter of 2021, the financial results of Meridian were reflected as discontinued operations. Prior-period financial information has been restated, as appropriate. See Note 1A .
[2]	At the beginning of our fiscal fourth quarter of 2021, we reorganized our commercial operations and began to manage our commercial operations through a new global structure consisting of two operating segments, each led by a single manager: Biopharma, our innovative science-based biopharmaceutical business, and PC1. PC1, which previously had been managed within the Hospital therapeutic area, includes revenues from our contract manufacturing, including certain Comirnaty-related manufacturing activities performed on behalf of BioNTech ($47 million for the first quarter of 2022), and revenues from our active pharmaceutical ingredient sales operation, as well as revenues related to our manufacturing and supply agreements with former legacy Pfizer businesses/partnerships, including but not limited to, transitional manufacturing and supply agreements with Viatris following the spin-off of the Upjohn Business. We have revised prior period information to conform to the current management structure.
[3]	Biosimilars are highly similar versions of approved and authorized biological medicines and primarily include revenues from Zirabev, Inflectra, Ruxience, Retacrit, and Trazimera.
[4]	Total Sterile Injectable Pharmaceuticals represents the total of all branded and generic injectable products in the Hospital therapeutic area, including anti-infective sterile injectable pharmaceuticals.
[5]	Prevnar family include revenues from Prevnar 13/Prevenar 13 (pediatric and adult) and Prevnar 20 (adult).
[6]	Immunoglobulin (Ig) portfolio includes the revenues from Panzyga, Octagam and Cutaquig.